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Abstract 
Several decades after the discovery of the human norovirus, with thousands of lives 
and billions of dollars lost, the lack of a robust cell culture system still severely 
hampers development of vaccines and therapeutics. This is likely in large part as a 
result of our limited understanding of the immune responses against an infection with 
the virus. Here, the presence of a RIG-I/STING-dependent innate response pathway 
that restricts the replication of noroviruses is described, and an attempt by the murine 
norovirus to subvert it through expression of an accessory protein is demonstrated. 
We show that both RIG-I and STING are required for a robust interferon response 
to infection with MNV1 in primary BMDMs and RAW264.7 cells, with a significant 
increase in viral titres following infection in RIG-I- and STING-deficient cells. We 
also show that STING is non-canonically activated in MNV1-infected cells partly in 
a RIG-I dependent manner. Furthermore, our data indicate that the MNV VF1 protein 
binds to STING and can inhibit interferon induction downstream of RIG-I. Secondly, 
while exploring the mechanisms for the differential induction of interferon sub-
types, we show that depletion of MED23 leads to a reduction in expression of both 
types I and III IFNs in human and mouse cell lines. We also show that Med23 
knockout cells undergo genetic compensation, suggesting a critical role for MED23 
in this pathway. Mechanistically, we show that MED23 interacts with IRF3, and is 
required for recruitment of RNA Polymerase II to promoters of IRF3-dependent 
genes. Taken together, our data indicate that MED23 plays a central role in antiviral 
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1.1. Enteric Caliciviruses 
1.1.1. Introduction and classification 
Caliciviridae is a family of positive-sense single-stranded non-enveloped RNA 
viruses with poly-adenylated RNA genomes ranging between 7.4-7.7kb, possessing 
2-4 open reading frames (ORFs), and able to infect both humans and animals
1–3
. The 
family is composed of five genera, including Norovirus, Sapovirus, Nebovirus, 
Lagovirus, and Vesivirus, among which noroviruses and sapoviruses cause disease in 
humans. Following the introduction of the rotavirus vaccine, they are increasingly 
becoming the commonest causes of infectious gastroenteritis worldwide
4–7
. Due to a 
lack of robust culture systems for either of the two human viruses, the murine 
norovirus (MNV, genus Norovirus), porcine sapovirus (genus Sapovirus), and feline 





Their genomes contain a long 5’ ORF that encodes a polyprotein that is subsequently 
processed into 6-7 non-structural (NS) proteins by the viral protease (NS6), a second 
ORF that encodes the major capsid protein VP1, and a short 3’ ORF that encodes the 
minor capsid protein VP2
2,8
 (figure 1.1). While both the non-structural proteins and 
VP1 in sapoviruses are encoded by the 5’ ORF (ORF1), some human and bat stains 
have a third predicted yet uncharacterised alternate ORF that overlaps the VP1 
sequence
9
. The MNV genome also has a similar alternate ORF overlapping the VP1 
sequence and encoding an accessory protein called virulence factor 1 (VF1)
10
. Like 
those of picornaviruses, the genomes of calicivirus are covalently linked to a small 
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The NS1/2, NS3 (viral NTPase), and NS4 are thought to play central roles in the 
formation of viral replication complexes, the NS5 protein (VPg) mediates translation 
of viral proteins, and the NS6 and NS7 are the viral protease and RNA-dependent 
RNA polymerase (RdRp), respectively
3,9


























Figure 1.1. Schematic representation of the genome organisation of the 
human sapovirus, HuNoV, and MNV. (Adapted from Goodfellow, I. (2012) in 
Reverse Genet. RNA Viruses 91–112). 
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icosahedral viral capsid (90 dimers), and the VP2 represents a minor component of 
the capsid (up to 2 copies)
2
. Although a virion contains the VP1, VP2 and VPg, the 
functions of the latter 2 in the virions are not well understood. Inside infected cells, 
the MNV VP2 protein was shown to counteract immune responses by inhibiting 
antigen presentation
11,12
. Because noroviruses decidedly include the more clinically 
important and most studied human virus within the Caliciviridae family3–5, all 
discussion beyond this point will be focused on them.  
 
1.1.2. Disease burden and clinical features of noroviruses 
The human norovirus has been implicated in 20% of all cases of diarrhoea, and causes 
up to 19 million illnesses every year
4,13
. It spreads primarily via the faeco-oral route 
and has an incubation period of 10-51 hrs
14
. The virus infects people of all ages, 
although the incidence is higher in children
4,14
. It is estimated that $4.2 billion (£3.3 
billion) is spent on norovirus-related healthcare, and $60 billion (£46.9 billion) is lost 
by society annually due to norovirus-related productivity losses
15
. Worldwide, up to 
200,000 thousand deaths have been reported, with severity of symptoms increasing 
significantly in young children, the elderly (>65 yrs.), organ transplant recipients, and 
people that are immunocompromised. An infectious dose as low as 18 is able to cause 
infection, and infected humans frequently present with diarrhoea (81%), vomiting 
(65%), abdominal cramps (68%), and occasionally fever (45%)
2,4,14
. Symptoms often 
resolve within 24-48 hrs in immunocompetent hosts
2
. Outbreaks often occur where 
there are large gatherings of people in confined spaces, such as nursing homes, cruise 




MNV has served as a surrogate model for studying the biology of noroviruses, owing 
to the lack of a robust culture system for the human norovirus
16,17
 (the recent 
development of a human intestinal enteroids model for culturing human noroviruses
18
, 
although remarkable, is currently still very expensive and difficult to establish). MNV 
can cause acute, lethal, or persistent infections in its natural host (mice), depending on 
the strain used and the genetic background of the host. For example, while infection 
with the acute strain of MNV in wild-type mice is asymptomatic, Stat1-/- and 
IFNαβγR
-/-
 mice present with severe diarrhoea, weight loss, and death within 2 weeks 
of infection
10,19,20
. Therefore, in addition to providing a tool for the study of norovirus 
biology, MNV provides a robust experimental system to understand viral 
pathogenesis, as well as the contribution of viral and host factors to viral persistence. 
 
1.1.3. Replication cycle of noroviruses 
Due to the absence of a robust cell culture system to grow the human norovirus, much 
of what is known about norovirus replication came from studies in MNV
3,21
. Cell entry 
during an infection with noroviruses is thought to occur by receptor-mediated 
dynamin II- and cholesterol-dependent endocytosis, followed by uncoating to release 
the VPg-linked viral genome into the cytosol
2,22
. Translation of the viral genome 
occurs in a VPg-dependent manner, and the viral polyprotein is then cleaved into 
mature non-structural proteins
21
. The non-structural proteins recruit host membranes 
to form peri-nuclear replication complexes, and the viral RdRp uses VPg as a protein 
primer for genome replication, although replication can also occur de novo21. De novo 
transcription by the RdRp produces a negative-strand RNA that serves as a template 
for both the genomic RNA and a VPg-linked subgenomic RNA that encodes the VP1 
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and VP2 proteins (and VF1 in MNV). It is not known if the negative-strand RNA is 
VPg-linked. Infected cells undergo apoptosis to release mature virions. 
 
1.1.4. Cell tropism 
Both acute and persistent strains of MNV were shown to be able to infect macrophages 
and dendritic cells in vitro early on after the discovery of the virus, although the in 
vivo tropism was not known at the time3,23. The recent determination of the 
proteinaceous receptor for MNV
24,25
, coupled with advances in in situ hybridisation 
assays allowed for the subsequent discovery of the in vivo tropism of MNV to myeloid 
cells, lymphocytes and tuft cells
26–28
. The human norovirus was also recently shown 
to infect a B-cell cell line (BJABs) and the enterocyte component of the human 
intestinal enteroids in vitro18,29. Its in vivo tropism is however not clear, although viral 
antigens have been detected in the intestinal epithelial cells of infected gnotobiotic 
pigs, lamina propria of a biopsy sample from an infected person, and dendritic cells 




1.2 Innate immune responses against RNA viruses 
1.2.1. General overview – Interferons and other cytokines 
Innate immunity encompasses an elaborate system of physical and chemical barriers, 
secreted and membrane proteins, as well as a myriad of effector cells that provide 
rapid non-specific protection from an invading pathogen. Central to innate immunity 
in a virus-infected host is the interferon (IFN) response, which includes a system of 
receptors that detect pathogens, a cascade mechanism that culminates in the induction 
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and expression of IFNs, and the generation of an antiviral state in the infected and 
nearby cells by the released IFNs (figure 1.2). IFNs induce expression of proteins that 
facilitate the resistance of host cells to viruses, activate immune cells recruited to the 
sites of infection and upregulate factors required for activation of adaptive immunity, 
all of which makes them critical in the control of viral infections. For this reason, and 
on account of the co-evolution of hosts and pathogens, any virus that is able to infect 




Other cytokines also play important roles in innate immune responses against RNA 
viruses. Chemokines and pro-inflammatory cytokines such as Tumour Necrosis 
Factor (TNF)α, interleukin (IL)-1β and IL-18 are also induced following detection of 
viruses by pattern recognition receptors (PRRs), largely following NF-kB activation, 
but also downstream of IFN receptors
32,33
. They complement IFN responses by 
recruiting macrophages, dendritic cells, natural killer cells and lymphocytes to sites 
of infection, and by mediating the inflammation response. While not as critical as IFN 
responses to individual infected cells, they contribute to the overall protection of the 









1.2.2. Intracellular detection of RNA viruses 
Viruses and other pathogens are detected by a myriad of receptors called pattern 
recognition receptors (reviewed by Iwasaki
34
, and by Brubaker et al.
35
). These 
receptors are present in various compartments in the host cell where pathogens might 
traverse and thus increasing the likelihood of their detection, including on cell surfaces 

































































































Figure 1.2. A simplified representation of the interferon response. (Adapted 
from Bowie & Unterholzner (2008), Nature Reviews Immunology 8, 911-922). 
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receptors), and in the cytosol (such as the retinoic acid-inducible gene 1 [RIG-I]-like 
receptors, NOD-like receptors, etc). They are germline encoded and are able to detect 
pathogen-aasociated molecular patterns (PAMPs) which are general molecular 
patterns unique to pathogens (such as uncapped 5’ tri-phosphorylated RNA), or 
common molecular signatures in aberrant conditions (such as the presence DNA in 
the cytosol). Activation of these sensors initiate signaling cascades that trigger the 
release of IFNs and other cytokines, and promote restriction of the invading pathogen.  
 
Yoneyama et al. demonstrated, for the first time, the ability of RIG-I to induce a 
TLR3-independent type I IFN secretion through IRF3 and NF-κB activation, in the 
presence of intracellular RNA
36
. They did this by showing activation of both IRF3 and 
NF-κB in cells overexpressing a truncated RIG-I construct containing both its CARD 
domains, following transfection of synthetic or viral RNA into the cells, as well as 
inhibition of the type I IFN response following RNA silencing of RIG-I expression. 
At around the same time, a similar role was demonstrated by Andrejeva and her 
colleagues for melanoma differentiation-associated protein 5 (MDA5), another 
DExD/H box helicase containing two N-terminal CARD domains.
37
 Together with 
LGP2, RIG-I and MDA5 form the RLR family and are implicated in the detection of 
the presence of most RNA viruses and some DNA viruses in an infected host cell.  
 
RIG-I-like receptors typically sense viral replication intermediates in the cytoplasm. 
RIG-I is thought to sense uncapped 5’-tri- and di-phosphorylated single-stranded or 
short double-stranded RNA, while MDA5 detects longer double-stranded RNA, all 





Activation of RIG-I or MDA5 by their cognate PAMPs triggers their oligomerization 
and recruitment to mitochondrial antiviral signalling protein (MAVS), which they 
activate via a homotypic CARD-CARD interaction. MAVS in turn recruits and 
activates downstream kinases, eventually leading to activation of transcription factors 
and expression of types I and III IFNs
38,40
. LGP2, although possessing an RNA-
binding helicase domain, lacks a CARD domain and thus is unable to bind MAVS
38,41
. 
It is thought to mainly act as a positive regulator of RIG-I and a negative regulator of 
MDA5 through as yet poorly understood mechanisms. 
 
1.2.3. Activation of MAVS, downstream kinases and transcription factors 
Four groups published independent findings demonstrating the role of the 
Mitochondrial Antiviral Signaling protein (MAVS, also known as CARDIF, VISA, 
and IPS-1) in the activation of IRF3 and NF-kB mediated by RNA virus infection and 
transfection of synthetic dsRNA.
42–45
 At the time, this discovery re-established the 
mitochondria as an essential organelle in innate immune responses, in addition to 
further elucidating the pathways of intracellular viral RNA recognition. MAVS is a 
membrane protein containing 540 amino acids and is abundantly expressed in all 
nucleated cells.
44–46
 Although the precise mechanistic details are still being worked 
out, it is generally accepted that MAVS plays a central role as an adapter in the 
intracellular recognition of RNA, as well as in apoptotic and metabolic pathways. 
40,47,48
 It has an N-terminal CARD domain that is involved in homotypic CARD-
CARD interactions with RIG-I and MDA5 during signal transduction. It also has a C-
terminal trans-membrane (TM) domain that anchors it to the outer mitochondrial 
membrane, peroxisomes or the mitochondria-associated endoplasmic reticulum 
11 
 
membrane (MAM), and a proline-rich region through which it interacts with other 
proteins.
45,49,50
 The CARD domain and the trans-membrane domains are both required 
for the canonical MAVS function. The proline-rich domain contains two TRAF-
interacting motifs, and a third motif is present close to the C-terminal end of the 
protein. MAVS has a predicted molecular weight of 72kDa, although a smaller 50kDa 
truncated form devoid of the CARD domain (termed miniMAVS) is also expressed in 
cells, and is believed to regulate the functions of the full-length protein.
46  
 
Signaling via MAVS causes it to oligomerize on the outer mitochondrial membrane 
in a prion-like manner, and culminates in activation of IRF3 and NF-κB, through 
induction of IKKε/TBK1 by TRAF3/IKKγ/TANK, and IKKα/IKKβ/IKKγ by 
TRAF6/RIP1, respectively. The requirement for TRAF6 here is thought to be 
redundant, as both TRAF2 and TRAF3 are sufficient for MAVS signaling in its 
absence.
40,47
 Activated IRF3 and NF-κB translocate into the nucleus to form an IFN 
‘enhanceasome’ that facilitates production of type I and III IFNs, which in-turn further 
stimulate cells in an autocrine and paracrine fashion, and eventually lead to a wide 
range of antiviral innate immune responses via induction of IFN stimulated genes 
(ISGs). 
 
The critical role played by MAVS in antiviral immunity was demonstrated in Mavs 
knockout mice. Murine embryonic fibroblasts (MEFs) from these mice had an 
impaired IFN and inflammatory cytokine secretion profile in response to transfected 
synthetic dsRNA (poly I:C) or following infection with Sendai virus, and showed a 
limited ability to restrict replication of Vesicular stomatitis virus (VSV).51 MAVS-
12 
 
deficient mice also showed significantly higher viral titers following intravenous 
injection of VSV or Encephalomyocarditis virus (EMCV) compared to wild-type 
mice, and increased mortality following intravenous injection of VSV.
51,52
 These 
findings corroborate the essential role of MAVS in the innate antiviral response to 
RNA viruses. 
 
The subcellular localization of MAVS was shown to be functionally critical. As 
alluded to earlier, the trans-membrane domain tethers the protein to the outer 
mitochondrial membrane, the peroxisomal membrane or the MAM, and absence of 
this localization leads to loss of function. One study in which the trans-membrane 
domain was modified so that MAVS was targeted only to the mitochondria 
(mitochondrial MAVS), the peroxisomes (peroxisomal MAVS) or has the trans-
membrane domain truncated so that it is not targeted to any organelle (cytosolic 
MAVS), attempted to unraveled the functional significance of this subcellular 
localization.
50
 A distinct immune response was seen with both the mitochondrial and 
peroxisomal MAVS, but not with cytosolic MAVS. Mitochondrial MAVS was seen 
to promote a delayed type I IFN-dependent induction of ISGs, while peroxisomal 
MAVS showed an early induction of ISGs in a type-I IFN-independent manner. This 
functional dichotomy was shown to be especially relevant in VSV infection where the 
virus evades immune responses by impairing transcription of type I IFNs. In this case, 
signaling via peroxisomal MAVS was shown to be essential in restricting viral 
replication. Further work by the same group showed this type I IFN-independent 
peroxisomal MAVS response in intestinal epithelial cells to be mediated by type III 
IFNs.
53
 The mechanistic determinants of this differential localization of the subsets in 
vivo and differences in the downstream signaling events are yet to be understood, and 
13 
 
recent attempts at replication by a different lab proved challenging
54
. Nevertheless, 
these findings clearly point to an advantage in the functional differences of the MAVS 
subsets. 
 
1.2.4. Intracellular sensing of DNA viruses 
Several PRRs involved in recognising the presence of viral DNA in the host cell have 
been described (reviewed by Ma and Damania
55
). The best characterised among them 
is the cyclic GMP-AMP synthase (cGAS), which catalyses the formation of cyclic 
dinucleotides that activate the adapter protein Stimulator of IFN Genes (STING) 
following detection of viral DNA
56
. Like MAVS, activated STING in turn recruits and 
activate downstream kinases and transcription factors, and in the process mediates 
induction of IFNs and proinflammatory cytokines. Other receptors shown to be 
involved in the detection of foreign DNA include DNA-PK, TLR9, AIM2, DAI, 
IFI16, DHX9, DHX36, DDX60, and MRE11. 
 
1.2.5. Crosstalk between MAVS and STING activation pathways 
The RLR/MAVS pathway of RNA sensing and the cGAS/STING pathway that detects 
foreign or aberrant DNA extensively collaborate to coordinate innate immune 
responses against invading pathogens (recently reviewed by Zevini et al.
57
). First, 
RIG-I contributes to detection of viral DNA through sensing of a dsRNA intermediate 
transcribed by RNA polymerase III
58,59
, while cGAS can detect DNA-RNA hybrids 
in the cytosol that are formed during the replication of retroviruses
60,61
. Additionally, 
infection with Dengue virus, a flavivirus, leads to leakage of mitochondrial DNA into 
the cytosol which is detected by cGAS
62,63
. Second, MDA5, RIG-I, STING, IRF1 and 
14 
 
IRF7 are all ISGs themselves, which means induction of IFNs by one pathway 
upregulates proteins that play central roles in the other, with the two pathways thereby 
potentiating activation of each other
57,64,65
. Third, STING, an adapter protein required 
for cytosolic DNA sensing, has been shown to promote IFN induction in cells infected 
with RNA viruses. For instance, it associates with both RIG-I and MAVS following 
activation of RIG-I in cells infected with SeV, and these interactions were found to 
promote induction of IFNs 
40,66,67
. Importantly, this was observed to be restricted to 
RIG-I activation, but not MDA5
40,67
. It was also demonstrated that STING can 
facilitate a fusion-mediated IFN induction in IAV-infected cells, in a cGAS-
independent manner, although the mechanistic details for this pathway are not yet 
known
68
. In cells infected with the Japanese Encephalitis virus (JEV), another 
flavivirus, STING is required for IFN induction downstream of RIG-I, and MAVS 
was seen to be dispensable in this case
69
. And lastly, STING was recently shown to 
inhibit translation in cells infected by a wide range of RNA viruses
70
. Altogether, these 
findings highlight an emerging theme of extensive crosstalk between the MAVS and 
STING pathways that underpins effective immediate and non-specific immune 
responses to a wide variety of invading pathogens. 
 
1.2.6. IFN induction in the nucleus 
Following virus-induced activation, the activated transcription factors translocate into 
the nucleus and bind to the IFN enhancer regions, composed of four positive 
regulatory domains (PRDs) in the case of IFN-β (reviewed by Ford and Thanos
71
, and 
recently by Au-Yeung and Horvath
72
). Activated NF-kB binds to PRDII, IRF3/7 bind 
to PRDI and III, and AP-1 binds to PRDIV, forming the IFN-β enhanceosome. 
15 
 
Transcription of the IFN genes is tightly controlled, and involves collaborative 
recruitment of histone acetyl transferases, chromosome remodelers, and other 





While the formation of the enhanceosome is required for a robust induction of type I 
and type III IFNs, recent studies suggest that activation of IRF3 preferentially 
promotes induction of IFN-β, while induction of type III IFNs is more dependent on 
activation of IRF7 and NF-kB
73–77
. The mechanistic details of this differential 
requirement of transcription factor activation is not yet known, considering the 
enhancers of both types I and III IFNs contain binding sites for both IRFs and NF-kB. 
One possible explanation is differential recruitment of co-activators by the different 
transcription factors. A recent paper described a function of MED23, a tail subunit of 
the Mediator complex, in triggering type III IFN-specific induction, following a 
genome-wide RNAi screen for host factors that inhibit replication of Herpes Simplex 
Virus type 1 (HSV1)
78
. Increased expression of type III IFNs was observed upon 
overexpression of MED23 in A549 cells, with a decrease in viral replication following 
infection with HSV1. Depletion of MED23 on the other hand, using a siRNA pool, 
lead to an increase in viral titres and a decrease in the induction of type III IFNs. The 
authors further demonstrated an interaction between MED23 and IRF7, but not 
between MED23 and other IRFs, concluding that MED23 specifically regulates 




The Mediator is a large multi-subunit protein complex that plays an essential role in 
transcription by recruiting the RNA Pol II pre-initiation complex to sites of 
transcription, and is required for transcription of all eukaryotic genes
79,80
.  It is divided 
into 4 distinct modules; the head and middle modules that form the core of the 
complex, a kinase module that is thought to form an autoinhibitory domain of the 
complex, and the tail module through which most gene-specific transcription factors 
interact with the complex. Several gene-specific transcription factors recruit RNA Pol 
II to promoter sites via interactions with specific tail subunits of Mediator
80–82
. It is 
therefore possible that another tail subunit mediates Mediator recruitment to activated 
IRF3. 
 
1.2.7. IFN signalling and induction of ISGs 
Released IFNs bind to their receptors on cell surfaces in an autocrine and paracrine 
manner. The IFN family in mammals consist of three groups; type I IFNs, including 
13 IFN-α subtypes, IFN-β, IFN-κ, IFN-δ, IFN-ε , IFN-τ , IFN-ω , and IFN-ζ; type II 
IFN, IFN-γ; and type III IFNs which include the IFN-λs (reviewed by Fensterl et al.
30
, 
and by Hoffmann et al.
31
). Human IFN-λs include IFN-λ1 (IL—29), IFN-λ2 (IL28A), 
IFN-λ3 (IL-28B), and IFN-λ4, but only IFN-λ2 and IFN-λ3 are functional in mice. 
Secretion of type II IFNs is restricted to specialized immune cells, whereas types I and 
III IFNs are ubiquitously expressed by all cell types, hence types I and III IFNs play 
larger more critical roles in innate responses against viruses
83
. While most cells can 
express IFN-α and IFN-β, plasmacytoid dendritic cells have the highest capacity of 







All 3 classes of IFNs signal through multi-subunit class II helical cytokine receptors 
encoded by genes located within the same cluster (reviewed by de Weerd et al.
86
). The 
type I IFN receptor (IFNAR) consist of 2 subunits, IFNAR1 and IFNAR2, each 
composed of a cytoplasmic component that associates with Janus Kinases (JAKs), a 
transmembrane domain, and an extracellular immunoglobulin-like domain that 
remarkably recognises all the diverse members of the type I IFNs. IFNAR1 associates 
with TYK2 while IFNAR2 associates with JAK1, and these kinases compensate for 
their lack of an intrinsic kinase activity. Similarly, the type II IFN receptor is 
composed of 2 subunits, IFN-γ receptor (IFNGR)1 and IFNGR2, while type III IFNs 
are composed of IFN-λ receptor (IFNLR)α and Interleukin (IL)-10 receptor (IL10R)β. 
The IFNAR and IFNGR are ubiquitously expressed in all cell types, although 
expression of specific subunits may differ from one cell type to another. In contrast, 
IFNLRα expression is chiefly limited to epithelial cells, hepatocytes and select 





Ligand binding leads to receptor clustering and auto-phosphorylation of the receptor-
associated JAK kinases – TYK-2/JAK1 in the case of IFNARs, JAK1/JAK2 for 
IFNGRs, and JAK1/JAK2 (or TYK-2/JAK1) for IFNLRs. This leads to 
phosphorylation of the receptors, and subsequently recruitment and phosphorylation 
of Signal transducer and activator of transcription proteins (STATs). Signalling 
downstream of both IFNAR and IFNLR leads to activation of STAT1/STAT2 





. ISGF3 then translocates into the nucleus to induce expression of IFN-
stimulated genes (ISGs) through binding to IFN-stimulated response elements (ISRE). 
On the other hand, binding of IFN-γ to the IFNGRs leads to activation of STAT1 
homodimers that binds to IFN-γ-activated sequence (GAS) in the nucleus. While both 
types I and III binding to their respective receptors largely leads to formation of the 
ISGF3 complex and induction of the same genes, type III IFN-stimulated genes have 
been shown to be only a subset of type I IFN-dependent genes. In addition, STAT1 
homodimers can form downstream of IFNAR-binding, which leads to induction of 




Although both type I and type III Interferons ultimately induce expression of the same 
ISGs, and hence produce parallel responses
93
, the specificity of type III Interferons 
lies in the differential expression of their receptors. Whereas the IFNAR receptors are 
abundantly expressed in most cell types, IFNLRα expression is limited to epithelial 
cells. This underpins the key roles of type III Interferons in innate immune responses, 
and is especially true against viruses that traverse mucosal surfaces where epithelial 
cells expressing the IFN-λ receptor are in abundance. A recent study showed that IFN-
λ is required for clearance of persistent norovirus infection in the intestines, for 
example, with increased fecal shedding seen in IFN-λ receptor-deficient mice over 35 
days of infection, but not in mice lacking type I interferon receptors.
94
 A similar 
finding was reported for rotavirus, in which there was an impaired control of viral 
replication within intestinal epithelial cells of IFNLRα-deficient mice, but not in 
IFNAR-deficient mice.
95
 In addition, recent work by Galani et al. showed that in mice 
infected with very low multiplicity of infection of influenza A virus (IAV) to mimic 
physiologic infection, an initial secretion of type III IFN was observed, characterized 
19 
 
by ISG induction with no pro-inflammatory cytokine expression and minimal 
inflammation
96,97
. It was only after this initial response was overcome by the viral 
infection that a second type I and III IFN response was observed, characterized by 
upregulation of both ISGs and pro-inflammatory cytokines, with significant 
inflammation and tissue damage. Altogether, these findings indicate the essential non-
redundant roles of type I and type III IFNs in host restriction of viruses. Despite 
considerable interest, however, the mechanism for the host’s ability to differentially 




1.2.8. Outcomes of IFN responses – the antiviral state 
The goal of the IFN response is to clear the infected cell of the pathogen, or if that 
fails, kill the one cell in order to save the whole organism and at the same time prepare 
neighbouring cells to resist infection. These goals are achieved by the upregulation of 
ISGs that induce a state of general resistance to all stages of the viral replication cycle 
via different mechanisms, termed ‘the antiviral state’. Hundreds of ISGs have been 
reported, out of which only a small fraction have known functions (reviewed by 
Schneider et al.
98
 and by Schoggins
83
). Among those already characterized are some 
of the central mediators of IFN induction, including RIG-I, MDA5, STING, IRF1, 
IRF7, and STAT1. Upregulation of these proteins provides a positive feedback loop 
that increases the efficiency of the IFN response. On the other hand, ISGs such as 
SOCS1 and USP18 are negative regulators of JAK/STAT signalling and act as brake 
systems that prevent development of immunopathology. Together, these opposing 
systems work in a balance that attempts to clear the cell of the infection while also 
limiting damage to the host. The majority of characterised ISGs are neither positive 
20 
 
nor negative regulators of the IFN response, however. Instead, they are mostly 
antiviral effectors that target different stages of the viral life cycle
64,98
. ISGs such as 
IFITMs, TRIM5α and the Mx proteins target viral entry and uncoating steps; RNAse 
L and IFIT1 degrade or sequester viral genomes; Viperin and ISG15 inhibit viral 
replication; PKR, STING and IFITs inhibit translation of viral proteins; and Tetherin 
prevents release of new virions
70,98–101
. Working together, these antiviral effectors 
ensure restriction of a broad range of viruses. 
 
1.2.9. Regulation of IFN responses 
Regulation of IFN responses ensures clearance of pathogens from infected cells while 
also minimizing immunopathology. This often occurs in the form of differential 
expression of protein isoforms, post-translational modifications (PTMs) or epigenetic 
changes relating to key proteins involved in the IFN response pathway (reviewed by 
Ivashkiv and Donlin
92
). For example, several mechanisms that regulate MAVS 
signaling have been described. A previous study characterized a shorter 50kDa variant 
of MAVS expressed from the MAVS gene via a complex interplay of leaky scanning 
events.
46
 This ‘miniMAVS’ was shown to attenuate the interferon inducibility of the 
full length MAVS, which suggests that it plays a modulatory role. Post-translational 
regulation of MAVS signaling is achieved by various host and viral proteins and 
occurs in the form of both ubiquitination and phosphorylation. In virally infected cells, 
MAVS is negatively regulated through K48-linked ubiquitination and subsequent 
targeting for proteosomal degradation by various E3 ligases such as TRIM25, AIP4, 
RNF5, and RNF125.
102–105
 Other negative regulators of MAVS, such as PLK1, bind 






1.3. IFN responses to noroviruses 
1.3.1 Restriction of Norovirus replication by IFNs 
Data from both in vivo and in vitro studies have established the capacity of IFNs to 
restrict replication of noroviruses. First, MNV infection of wild type mice is largely 
asymptomatic, in contrast to Stat1-/- or IFNαβγR-/- mice in which infection is 
accompanied by a considerable increase in viral RNA and causes severe symptoms, 
significant multi-organ pathology, and death in all infected mice within 2 weeks of 
infection
19,20
 – this increased susceptibility can be reversed by administration of IFN-
λ
107
. Secondly, treatment of MNV-infected cells with recombinant IFN-β significantly 
inhibits viral replication, as is treatment of mice with IFN-λ
27,108,109
. Similarly, TLR7 
agonists and plant extracts (Schizonepeta tenuifolia Briquet) were shown to 
significantly inhibit MNV replication by promoting IFN induction
110,111
. Likewise, 
over-expression of RIG-I and MDA5 was shown to inhibit MNV replication, likely 
by inducing IFN induction
112
. In vivo experiments in mice showed a context-
dependent differential requirement of type I and type III IFNs in which type I IFNs 
protect against systemic spread via immune cells while type III IFNs restrict enteric 
persistence
94
. Lastly, selective knockout of Ifnar1 in dendritic cells allows an 
otherwise acute strain of MNV (CW3) to persist, despite the presence of a functional 
adaptive immune system
113
. This was recently shown to occur due to an IL-1α-
mediated recruitment of monocytes and neutrophils, in a manner dependent on lytic 
cell death induced by the viral capsid
114
. While there are no data on the restriction of 
human norovirus replication by IFNs in human subjects, gnotobiotic pigs infected 





. Treatment of human norovirus replicon-harbouring HG23 cells with IFN-α 
was shown to result in a reduction in viral genomes in a dose dependent-manner
116,117
. 
Moreover, treatment of cells with cell culture supernatant from poly (I:C)-transfected 
cells inhibited replication of human norovirus RNA in Huh-7 cells
118
. Overall, these 
studies show the capacity of IFNs to inhibit replication of noroviruses. 
 
The specific ISGs responsible for inhibiting norovirus replication are not all known. 
Pre-treatment of cells with recombinant IFN-β or IFN-γ was shown to inhibit 
translation of viral proteins without affecting viral genome integrity
108
. This inhibition 
was shown to be independent of PKR and RNAse L for the IFN-β-pre-treated cells, 
but not in IFN-γ-pre-treated cells, indicating the presence of another ISG(s) that 
inhibits viral translation. Several ISGs have since been shown to generally inhibit 
translation of viral proteins via disparate mechanisms (reviewed by Li et al.
119
), but 
their functions have not been looked at in the context of a norovirus infection. ISG15 
is among the few ISGs clearly implicated in restricting norovirus replication
109
. 
Higher viral titres were obtained from IFN-α-treated IS15-deficient bone marrow-
derived macrophages (BMDMs) compared to wild-type cells, indicating a role for 
ISG15 in IFN-dependent control of MNV replication. This function was shown to be 
at the level of viral entry or uncoating, as replication in MEFs transfected with the 
MNV RNA was not affected by the absence of ISG15. Other ISGs shown to counteract 
norovirus replication include NLRP6, IRF1, IRF7, IFN-λs, STAT1, MHCII, and 
β2M
120
. It should be noted that limited levels of ISGs are seen in MNV-infected cells 
as the virus has been shown to inhibit ISG translation through at least 2 independent 
mechanisms
109,121
 (discussed in greater detail below under ‘Counteraction of IFN 




1.3.2. IFN induction during Norovirus infections 
Robust induction of type I and type III IFNs are seen following infection with MNV 
both in vivo and in vitro20,121–125. In mice, IFN-β is detected in intestinal homogenates 
as early as 12 hrs following per-oral inoculation, and in the serum within 24 hrs of 
infection
20
. In vitro, while an increase in transcripts is seen early during infection, IFN 
release appears to be temporally different in cell lines compared to primary cells, with 
IFN-β secretion seen within 4 hrs of infection in BMDMs, and 20 hrs in RAW264.7 
macrophage cell line
124
. This unexplained delay in IFN release is potentially 
responsible for the higher viral titres seen in macrophage cell lines compared to 
primary macrophages and dendritic cells. 
 
In contrast to MNV, there was no evidence of IFN induction in Huh-7 and 293FT cells 
transfected with the human norovirus RNA
118,126
. Cell culture supernatant from poly 
(I:C)-transfected cells was able to inhibit replication of human norovirus in Huh-7 
cells, but not that from norovirus RNA-transfected cells
118
. In 293FT cells, there was 
no IFN induction following transfection of human norovirus RNA compared to 
control RNA
126
. Replication of the human norovirus did not interfere with the IFN 
response pathway as secondary transfection of poly (I:C) and infection with Sendai 
virus (SeV) in the norovirus RNA-transfected cells led to a robust induction of IFN-
β. Interestingly, siRNA depletion of MAVS and IRF3 did not affect levels of viral 
genome copies. This contrasts with data from work in gnotobiotic pigs, where an 
increase in IFN-α and IFN-γ were seen as early as 24-48 hrs after infection, with a 





One caveat with the in vitro experiments is that in both the Huh-7 and 293FT studies, 
purified RNA was used from stools of norovirus-infected humans which may contain 
other contaminating RNA. Also, virus replication seen in these cells was only 
marginal. Nevertheless, these preliminary studies offer the only available account of 
IFN responses to the human norovirus in cell lines, in the absence of a robust culture 
system, and highlight the increasing need for more work in this area. 
 
In terms of the mechanism of IFN induction, MDA5 was shown to play a central role 
in the innate immune response to both acute and persistent strains of MNV
122,123
 
(figure 1.3). Near-baseline levels of IFN-α were seen in bone marrow-derived 
dendritic cells from MDA5-deficient (Ifih1-/-) mice following infection with an acute 
strain of MNV (CW3) compared to the wild type, with a significant increase in viral 
titres seen in the spleen, mesenteric lymph nodes (MLN) and proximal intestines of 
Ifih1-/- mice. The role of MDA5 in restricting MNV replication was shown to be 
completely IFN-dependent, as similar viral titres were obtained from wild-type and 
Ifih1-/- cells following pre-treatment with IFN-α. Surprisingly, while higher viral titres 
were seen in Ifih1-/- mice infected with a persistent strain of MNV (CR6), there was 
no difference in wild-type and Ifih1-/- bone marrow-derived dendritic cells 
(BMDCs)
123
. The authors speculate that the inability of BMDCs to sense type III IFNs 
accounts for this disparity, although it could also indicate a strain-specific role for 
other PRRs.  At the same time, the increase in viral titres observed in Ifih1 knockout 
mice and BMDCs infected with acute strains of MNV are only moderate, and MNV 
infection is not lethal in Ifih1 knockout mice in contrast to Stat1 knockout mice19,122, 







TLR3, TLR7, and presumably TLR8 (via Myd88) do not appear to play any role in 
IFN responses to noroviruses in vitro, although a marginal increase in viral titres was 
observed in the MLNs of Tlr3-/- mice122,123. Interestingly, no published study has 
examined MNV infection in RIG-I-deficient (Ddx58-/-) cells. In a recent study looking 
at RIG-I inhibition by a bacterial quorum-sensing molecule, it was shown that while 
treating cells with the molecule led to a moderate increase in SeV titres in HEK293T 
cells, it did not appear to affect MNV titres in RAW264.7 cells
129
. It is however not 
clear whether there was any effect on IFN induction by the MNV infection or if the 
dose used was sufficient. Also, no statistically significant difference was observed in 
viral replication following transfection of the human norovirus RNA in Huh-7 and 
RIG-I-deficient Huh-7.5, although norovirus replication in these cell lines did not 















The NOD-like receptor family pyrin domain containing 6 (NLRP6) protein was also 
shown to contribute to cytosolic detection of MNV, likely in a manner dependent on 
the RNA helicase DHX15
131
. Increased – though modest – viral titres were obtained 














































Figure 1.3. Mechanism of IFN induction in norovirus-infected cells. Pathogen-
associated molecular patterns (PAMPs), generated from virus replication, are 
thought to be detected by MDA5 and NLRP6, leading to activation of MAVS at 
mitochondria and peroxisomes. Activated MAVS in turn activate downstream 
kinases, TBK1 and IKKε, which recruit and phosphorylate IRF3 and IRF7. This 
results in their dimerization and translocation into the nucleus, where they induce 
expression of type I and type III interferons. The interferons produced are then 
released to act on cells in an autocrine and paracrine manner. Although clear 
experimental evidence is lacking, it is likely that additional pattern recognition 




type, with faecal shedding persisting beyond 8 days post-infection. The authors 
demonstrated an inverse relationship in the expression of MDA5 and Nlpr6 in 
intestinal epithelial cells and myeloid cells in the gut, with higher levels of MDA5 in 
myeloid cells and NLRP6 in intestinal epithelial cells, and posit that NLRP6 likely 
compliments MDA5 detection of viruses in epithelial cells.  
 
The phenotypic differences between MNV-infected MDA5 and STAT1 knockout 
mice are unlikely to be explained solely by the contribution of NLRP6 in norovirus 
detection, indicating a role for other receptors (Figure 2).  As discussed above, while 
the presence of VPg was always thought to protect the viral genome from RIG-I 
sensing
122,132
, there is currently insufficient experimental evidence to rule it out as a 
sensor of noroviruses. Moreover, recent studies on picornaviruses and on the Tulane 
virus show that RIG-I can still detect viruses that have VPg-linked genomes
133–136
. 
Other PPRs can also potentially participate in the recognition of noroviruses. The 
DNA sensor cGAS, for example, was recently shown to indirectly recognise infection 
with dengue viruses by sensing leaked mitochondrial DNA
62,137
. The release of 
mitochondrial DNA into the cytosol was shown to occur downstream of IL-1β
137
, a 
proinflammatory cytokine abundantly secreted by MNV-infected cells
138
. While this 
pathway is not present in cells infected with many other RNA viruses
70
, whether it 
occurs in norovirus-infected cells remains to be explored. A recent study suggested 
that the capsid-detecting TLR2, expressed on cell surfaces, can bind HuNoV virus-
like particles, although it is not known if this potential interaction leads to an IFN 
response
139
. The endosomal TLR10 was also recently shown to be able to recognise 
dsRNA in cells, and may therefore be involved in sensing noroviruses
140
. Taken 




Downstream of the PRRs, MAVS, IRF3 and IRF7 have all been shown to play central 
roles in induction of IFN following infection with MNV
120,123
. Heme-oxidized IRP2 
ubiquitin ligase 1 (HOIL1), a component of the linear ubiquitin assembly complex 
(LUBAC), was also recently shown to contribute to IFN induction in MNV-infected 
mice, and the authors speculated that it likely acts downstream of MDA5
123
. Like in 
MDA5-deficient mice, HOIL1-deficient (Rbck1-/-) mice infected with a persistent 
strain of MNV (CR6) had higher viral titres in the stool, colon, ileum and MLN, and 
no difference in viral titres in BMDMs despite a significant reduction in IFN 
induction. However, direct mechanistic evidence connecting MDA5 and HOIL1 
remains to be uncovered, and the levels of the SHANK-associated RH31 domain-
interacting protein (SHARPIN) were also consistently reduced in the cells used 
indicating possible alternative explanations for the phenotypes observed. Moreover, 
the LUBAC complex has previously been shown to inhibit RLR signalling, while also 
activating NEMO and IRF3-dependent apoptosis
141–143
. Nevertheless, these studies 
indicate a complex role for linear ubiquitination in controlling infections with RNA 
viruses and more work is thus required to understand it. 
 
IFN induction in norovirus-infected cells appears to be replication-dependent, as no 
IFNs were detected following infection with gamma-irradiated virus or transfection 
of proteinase K-treated MNV RNA in BMDCs
122
. No other published study has 
examined the cognate PAMP recognised by host PRRs in cells infected with 
noroviruses, although it has been shown that the MNV polymerase can transcribe 





candidate PAMPs for MDA5 will include the dsRNA intermediates and VPg-linked 
subgenomic RNA produced during viral genome replication
145
 (discussed above). 
Single-stranded negative sense RNA intermediate that is likely not VPg-linked is also 
produced, and could be a potential ligand for other host PRRs such as RIG-I. 
 
1.3.3. Counteraction of IFN responses by Noroviruses 
The virulence factor 1 (VF1) protein is the first norovirus protein shown to antagonize 
the IFN response
10,11,146
. It is a small 213-amino acid protein encoded by an alternate 
open reading frame overlapping the VP1 sequence. It is present only in MNV and is 
not encoded by human noroviruses. Much of its structure is not known, but data from 
our lab (Mcfadden et al.
10
, and unpublished data generated by Dr. Frederic Sorgeloos 
and I) suggest that it is a multi-pass membrane protein with a free cytosolic amino-
terminal end and a carboxyl-terminus largely embedded within the outer 
mitochondrial membrane. RAW264.7 cells infected with MNV1-M1, a VF1-deleted 
mutant, showed an increased induction of IFN-β and an impaired ability to activate 
apoptotic pathways compared to those infected with the  wild-type virus
10
. Deletion 
of VF1 exacts a fitness cost on the virus in RAW264.7 cells and the M1 mutant 
reverted to wild-type virus after 3 passages. Although the mechanism is not clear, VF1 
inhibited IFN induction after over-expression of RIG-I, MDA5, MAVS, and TBK1, 
indicating that it likely acts downstream of TBK1 activation
10,11
. Mice infected with 
MNV-M1 show decreased viral titres on days 3 and 5 in all tissues tested, including 
MLNs, spleen, liver, kidney, intestine, heart, lung and faeces, compared to those 
infected with the wild-type virus
10
. Infection with the MNV-M1 virus in Stat1-/- mice 
led to significant reduction in weight loss and intestinal pathology. Taken together, 
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these findings demonstrate a defined strategy by MNV to counteract IFN responses 
through expression of VF1, although the exact mechanism and target of this action 
have not been determined. 
 
Limited levels of ISGs are seen in MNV-infected cells, as the virus inhibits ISG 
translation via at least 2 possible mechanisms
109,121
. First, the viral protease was shown 
to cause cleavage of poly A-binding protein PABP, required for cap-dependent, but 
not VPg-dependent, translation
121,147
. Cleavage occurs at position Q440 of PABP and 
allows for a disruption of host translation while translation of viral proteins occurs 
unimpeded. Secondly, MNV infection triggers apoptosis and caspase-dependent 
cleavage of eIF4E
121
. While the specific role of eIF4E in the replication of MNV is 
not clear, its depletion affects cap-dependent translation of host proteins, but does not 




Although the mechanism still remains to be tested, the MNV NS1 protein mediates 
persistence of the CR6 strain of MNV in mouse intestinal epithelial cells, specifically 
the CD300lf+ Tuft cells
27,28,150–152
. Replacing the CR6 NS1 with that of CW3, the 
acute strain, led to clearance of the persistent virus, while replacing the CW3 NS1 
with that of CR6 led to persistence of the acute strain in intestinal epithelial cells
27
. 
While the intestinal epithelial cells express the IFNLR1 and respond readily to type 
III IFNs, they show a minimal response to type I IFNs
153
, and persistence in them 
therefore allows for escape from type I IFN responses. Interestingly, wild-type CW3 
MNV was also shown to persist in the absence of the IFNLR1, indicating potential 






Other strategies deployed by noroviruses to evade IFN responses have been proposed 
(reviewed by Roth and Karst
146
). First, the human norovirus non-structural proteins 
p22 and p48 were implicated in Golgi disassembly and disruption of ER-Golgi 
trafficking of cellular proteins and thereby potentially impairing cellular secretory 
pathways utilized for release of IFNs
146
. The mechanism for this activity is still under 
investigation, and its direct effect on IFN responses in the context of a viral infection 
remains to be tested. Secondly, considering that no evidence of IFN induction was 
observed in Huh-7 and 293FT cells harbouring human norovirus RNA, it has been 
suggested that the viral genomes could be sequestered within replication complexes 
and away from the RLRs
118,126
. While both RIG-I and MDA5 can be recruited to stress 
granules in virus-infected cells, the presence of MDA5 in viral replication complexes 
has not been reported
154–156
. Further work is warranted to confirm these, and other 
potential strategies employed by noroviruses to evade IFN responses.  
 
1.3.4. Outstanding questions 
While MDA5 has been established as a bona fide PRR in MNV-infected cells, other 
PRRs likely contribute, considering MNV infection is lethal in Stat1-/- mice but not in 
Ifih1-/- mice. Current available data129,130,144  provide support for and against RIG-I as 
a PRR in MNV-infected cells, and warrants future examination of its role in norovirus 
restriction. Additional work is also required to determine the cognate PAMPs 




Regulation of IFN responses by the MNV VF1 protein has been demonstrated, but the 
mechanism by which it executes this is still unclear. Preliminary mechanistic work by 
McFadden et al.
10
 using protein over-expression assays indicate that it acts 
downstream of TBK1. As a transmembrane protein on the outer mitochondrial 
membrane, it could potentially interfere with the MAVS/TBK1/IRF3 complex either 
directly or by modulating the mitochondrial membrane potential. VF1 also appears to 
interact with TOM70 (Nora McFadden, unpublished PhD thesis) which itself 
participates in signalling downstream of MAVS
157,158
, and may therefore interfere 
with the TOM70-dependent activation of MAVS. However, this potential interaction 
could also be unrelated to IFN signalling as most proteins on the outer mitochondrial 
membrane require TOM70 for membrane insertion
159
. Nevertheless, future studies are 
needed to further understand the function of VF1, and other potential strategies 
deployed by noroviruses to evade host innate immune responses. 
 
1.4. Thesis objectives 
This thesis aims to: 
1. Define additional innate immune mechanisms employed in the 
detection of MNV1 
2. Clarify the mechanism of VF1 antagonism of host IFN responses. 



















RAW264.7, BV2, A549, HaCat, HEK293T, and HeLa M cells were maintained at 
37
o
C in complete Dulbecco’s Modified Eagle Medium (DMEM, Sigma Aldrich) 
containing 4500mg/ml glucose, sodium bicarbonate, and sodium pyruvate, and 
supplemented with 10% heat-inactivated Fetal Bovine Serum (HyClone), 10U/ml of 
penicillin, 100 µg/ml of streptomycin, 2mM L-glutamine (Sigma Aldrich), and non-
essential amino acids (Sigma Aldrich). A549 cells used in this work were a kind gift 
from Dr Rachel Ulferts (University of Cambridge) and the HaCat, HEK293T and 
HeLa M cells were generously provided by Dr Susanna M. Calaco (University of 
Cambridge). mCherry-PTS1 HeLa M cells expressing an mCherry protein engineered 
to localise to peroxisomes and HEK293T stably-transduced with mouse CD300lf were 
provided by Dr Frederick Sorgeloos (University of Cambridge UK and De Duve 
institute Belgium).  
 
BSR-T7 cells, a kind gift from Karl-Klaus Conzelmann (Ludwid Maximillians 
University, Munich) derived from Baby Hamster Kidney (BHK) cells and expressing 
the T7 RNA polymerase, were maintained in complete DMEM supplemented with 0.5 
mg/ml G418 (Invivogen). 
 
Med23+/+ and Med23-/- murine embryonic fibroblasts made from 8-week old embryos 
described in Stevens et al.160 and Balamotis et al.161, were maintained at 37oC in 
Knockout DMEM (Gibco) supplemented with 15% Fetal Bovine Serum (HyClone), 
2 mM L-Glutamine (Sigma Aldrich), 50 µg/µl Penicillin/Streptomycin, 0.1 mM non-
essential amino acids (Sigma Aldrich) and 100 µM beta-mercaptoethanol (Gibco). 
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Both cell lines were kindly provided by Professor Arnold Berk (University of 
California, Los Angeles). 
 
Bone marrow-derived macrophages (BMDMs) were differentiated from bone marrow 
cells of C57BL/6 mice as previously described
162
. Briefly, bone marrow cells were 
seeded on non-treated culture plates in complete DMEM supplemented with 10% 
CMG14 culture supernatant which contains M-CSF. Fresh medium was added every 
3 days and cells were harvested and used for experiments on 9 or 10. Ddx58+/+ and 
Ddx58-/- bone marrow cells were kindly provided by Adolfo Garcia-Sastre (Icahn 
School of Medicine at Mount Sinai in New York). All other bone marrow cells used 
were provided by Yasmin Goodfellow (University of Cambridge). 
 
Plasmids 
Plasmids used in this work are listed in Table 2.1. 
Table 2.1: List of plasmids used 
sn Name Insert/description Source Comments 
1. pT7:MNV-
1_3’Rz 
MNV1 WT cDNA 
clone 
Chaudhry et al. 
2007163 




MNV1 M1 cDNA 
clone 
McFadden et al. 
201110 
Similar to pT7:MNV-1_3’Rz, 
but with a T5118A mutation 
that introduces a stop codon 
17 amino acids downstream of 
the VF1 start codon and a 
silent mutation in VP1 
3. pFS669IG Mouse CD300lf Frederic 
Sorgeloos 
 
4. pAJ034IG Bicistronic with 
MNV1 VF1 and 
mCherry 










6. pMDLg/pRRE Encodes Gag and 





3rd generation lentiviral 
packaging plasmid 
7. pRSV-Rev Encodes Rev Frederic 
Sorgeloos 
3rd generation lentiviral 
packaging plasmid 




3rd generation lentiviral 
packaging plasmid 












MISSION shRNA plasmid 
TRCN0000346266 





MISSION shRNA plasmid, 
TRCN0000341925 





MISSION shRNA plasmid, 
TRCN0000341853 





MISSION shRNA plasmid, 
TRCN0000218197 





MISSION shRNA plasmid, 
TRCN0000229869 





MISSION shRNA plasmid, 
TRCN0000229868 
16. pAJ118IG HA-STING This work Cloned via digestion/ligation, 
cDNA template from MEFs; N-
terminal tag; mouse 
17. pAJ116IG- HA-EGFP This work Gateway cloning; N-terminal 
tag 
18. pAJ025IG HA-VF1 This work Gateway cloning, codon-
optimised; N-terminal tag 
19. pAJ182IG HA-MED23 This work Gateway cloning, cDNA 
template from HeLa M cells; 
N-terminal tag, human 




21. pAJ117IG FLAG-STING This work Cloned via digestion/ligation, 
cDNA template from MEFs; N-
terminal tag; mouse 
22. pAJ024IG FLAG-VF1 This work Gateway cloning, codon-
optimised; N-terminal tag 
23. pAJ111IG FLAG-IRF3-5D This work Constitutively active IRF3 
mutant (S388D, S390D, 
S394D, T396D, and S397D); 
Gateway and Overlap 
extension PCR cloning, cDNA 
template from MEFs; N-
terminal tag, mouse 
24. pAJ175IG EGFP-MED23 
isoform 1 
This work Cloned via digestion/ligation, 
cDNA template from HeLa M 
cells; N-terminal tag, human 
25. pAJ176IG EGFP-MED23 
isoform 2 
This work Cloned via digestion/ligation, 
cDNA template from HeLa M 
cells; N-terminal tag, human 
26. pAJ177IG EGFP-MED23 
isoform 6 
This work Cloned via digestion/ligation, 
cDNA template from HeLa M 
cells; N-terminal tag, human 
27. IFN-b-luc IFN-b promoter-
driven firefly 
luciferase 
Andrew Bowie  
28. IFN-l1-luc IFN-l1 promoter-
driven firefly 
luciferase 
Jurgen Haas  
29. NF-kB-luc Firefly luciferase 




Andrew Bowie  
30. pRL-TK TK promoter-
driven renilla 
luciferase 
Andrew Bowie  
31. pAJ120IG Flag-p65 This work Cloned via digestion/ligation, 
cDNA template from MEFs; N-
terminal tag, mouse 
32. p65-HA Human p65 Irina Udalova C-terminal tag 
33. pBent2 Empty vector Irina Udalova control vector for p65-HA 
34. pTM942 Empty vector Frederic 
Sorgeloos 
Bicistronic with MCS and 




35. pFS420 Empty vector Frederic 
Sorgeloos 
control vector for all plasmids 
used except pAJ168IG, p65-
HA, and pCR3-IRF7 
36. pAJ007IG Flag-MAVS This work Gateway cloning, cDNA 
template provided by 
Jonathan C Kagan; N-terminal 
tag, otherwise wild type, 
human 
37. pAJ014IG Flag-mito-MAVS This work MAVS with its TMD replaced 
by the targeting sequence of 
Bcl-xl; Gateway cloning, cDNA 
template provided by 
Jonathan C Kagan 
38. pAJ010IG Flag-cyto-MAVS This work MAVS with its TMD deleted; 
Gateway cloning, cDNA 
template provided by 
Jonathan C Kagan 
39. pAJ008IG Flag-pex-MAVS This work MAVS with its TMD replaced 
by the targeting sequence of 
Pex13; Gateway cloning, 
cDNA template provided by 
Jonathan C Kagan 
40. pAJ168IG Human MED23 This work Bicistronic with mCherry; 
Gateway cloning, cDNA 
template from HeLa M cells 
41. pCR3-IRF7 Human IRF7 Jurgen Haas N-terminal HA tag 
42. pCR3 Empty vector Jurgen Haas control vector for pCR3-IRF7 
 
SiRNA transfection 
SiRNA transfections were carried out using Lipofectamine RNAiMAX (Invitrogen) 
according to the manufacturer’s protocol. Briefly, cells were seeded in 10cm dishes 
overnight. On day 2, 30μ Lipofectamine RNAiMAX and 150pmol siRNA were each 
diluted in 500μl Opti-MEM reduced serum media (ThermoFisher Scientific), 
following which the two were mixed and incubated at room temperature for 5 minutes, 
and then added dropwise onto the cells. The cells were then incubated at 37oC for 
48hrs and then assessed for knockdown or were re-seeded for downstream 
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experiments. The siRNA used in this work include siMED23-1 <5′-
aggcaaagaagttgggaat-3′> (previously reported
164,165




For shRNA transduction, Mission shRNA plasmids (Sigma Aldrich) were transfected 
together with pMDL g/p RRE, pRSV-Rev, and pMD2G plasmids into HEK293T cells 
using Lipofectamine 2000. Pooled lentiviral supernatants harvested on days 2 and 3 
were used to infect RAW264.7 cells, HeLa M cells, HaCat cells, HEK293T cells, 
A549 cells, and Med23+/+ and Med23-/- MEFs. Puromycin (Invitrogen) selection was 
started 72 hrs post-infection. The MEFs and RAW264.7 cells were cultured in 2 μg/ml 
puromycin until all the control cells were dead and was then maintained in 5 μg/ml 
puromycin. All the other cell lines were cultured in 1.5 µg/ml puromycin until all the 
control cells were dead and was then maintained in 5 µg/ml puromycin.  
 
For CD300lf, VF1, and EGFP lentiviral transduction, the pFS669IG, pAJ034IG and 
pFS341 plasmids, respectively, were transfected together with pMDL g/p RRE, 
pRSV-Rev, and pMD2G plasmids into HEK293T cells using Lipofectamine 2000. 
Pooled lentiviral supernatants harvested on days 2 and 3 were used to infect HeLa M 
cells. CD300lf-transduced HeLa were subsequently selected using 100 µg/ml 










 BSR-T7 cells were seeded in a 6-well plate and incubated at 37
o
C for 
3 hrs. The cells were then infected with Fowl pox virus (FPV)-T7 at an MOI of 0.5 
pfu/cell in 700μl of cell culture media and incubated at 37
o
C for 2 hrs (2ml of 
antibiotic-free media was added 1 hr into the infection). Then, 1μg of the pT7:MNV-
1_3’Rz or the pT7:MNV-1_3’Rz_M1 MNV cDNA clones (for the wild type or VF1-
deficient M1 mutant, respectively) were transfected using Lipofectamine 2000, 
according to the manufacturer’s instructions. The plate was incubated at 37
o
C for 2 
days, freeze-thawed once (at -80
o
C overnight or longer), and titred by TCID50. 
 
TCID50 
TCID50 by cytopathic effect (CPE) was carried out as previously described
145
. 
Briefly, 1:10 serial dilutions of the virus preparations were made in cell culture media 
and aliquoted into wells of a 96-well plate, each in 4 replicates of 50μl. Then, 2x10
4
 
RAW264.7 cells in 100μl of cell culture media was added to each well and the plate 
was incubated at 37
o
C for 5 days. The cells were subsequently assessed for CPE, and 




Cell stimulation and infection 
Poly (I:C) (P1530, Sigma) and poly (dA:dT) (P1537, Sigma) transfections were 
carried out on cells seeded in 24-well plates overnight using Lipofectamine 2000, 
according to the manufacturer’s protocol. For the MNV and EMCV infection 
experiments for RT-qPCR, cells seeded in 24-well plates overnight were incubated in 
500 µl of prewarmed fresh media alone or media containing the appropriate amount 
41 
 
of virus at 37
o
C. The media was changed after 1 hr and the cells were incubated at 
37
o
C for 12 hrs before harvesting for downstream experiments. Infections for western 
blotting were carried out in the same way but often scaled up to 10cm dishes or T150 
flasks. The EMCV is a kind gift from Dr Frederick Sorgeloos (University of 
Cambridge UK and De Duve institute Belgium). 
 
For experiments involving STING inhibition, cells were pre-treated in DMSO 
(Sigma), C-176 (Focus Biomolecules), or H-151 (Focus Biomolecules) for 2 hrs 
before infection or transfection with poly (I:C) or poly (dA:dT), and the drugs are 
supplemented in the media onwards until the cells are harvested for end-point assays. 
For experiments involving cGAS inhibition using RU.521 (Invivogen), cells were pre-
treated for 3 hrs before infection or transfection, and the drug is supplemented in the 
media onwards until the cells are harvested for end-point assays. 
 
Luciferase assay 
Cells seeded in 24-well plates overnight were transfected with 180ng of the indicated 
firefly luciferase plasmid and 20ng of the renilla control plasmid, in addition to the 
expression or empty vectors, using Lipofectamine 2000 and according to the 
manufacturer’s protocol. The media was changed 6 hrs after transfection and the cells 
were harvested after 24 hrs. For assays involving poly (I:C), cells were either mock 
transfected or transfected with the indicated amounts poly (I:C) 24hrs after the initial 
transfection and were harvested after 6 hrs. Cells were harvested in 100 µl of passive 
lysis buffer, and the samples were analysed in a Glomax luminometer. To calculate 
the fold induction, the raw relative luciferase unit (RLU) values of the firefly 
42 
 
luciferase were initially normalised to those of the renilla luciferase, and the results 
were divided by the average of the mock control (empty vector). 
 
Cell fractionation  
Cell fractionation was carried out based on a modified REAP protocol
167
. Briefly, the 
cells were washed in 1 ml of ice-cold PBS twice by centrifuging at 10,000 xg for 10 
seconds at 4
o
C. The cells were then resuspended in 500 µl CF1 lysis buffer (50 mM 
Tris pH8, 2 mM EDTA, 1% NP-40) supplemented with a protease inhibitors cocktail 
by pipetting up and down 5 times and 50 µl was aliquoted into a new tube as the whole 
cell fraction. The remaining sample was centrifuged immediately at 10,000 xg for 10 
seconds at 4
o
C, and 50 µl of the supernatant was aliquoted into a new tube as the 
cytoplasmic fraction. The remaining supernatant was discarded, and the pellet was 
resuspended in 500 µl of CF1 buffer and was centrifuged immediately at 10,000 xg 
for 10 seconds at 4
o
C. The supernatant was discarded, and the pellet was resuspended 
in 60 µl CF2 buffer (50 mM Tris pH8, 2 mM EDTA, 1% NP-40, 250 mM NaCl), kept 
on ice for 10 minutes, and centrifuged at 10,000 xg for 10 minutes at 4
o
C. The 
supernatant was transferred into a new tube as the nuclear fraction. To adjust the final 
NaCl concentration to 150 mM, 75 µl of CF2 was added each to the whole cell and 
cytoplasmic fractions, and 20 µl of CF1 buffer to the nuclear fraction. The samples 
were mixed with western blotting buffer (2% SDS, 10% glycerol, 0.002% 
bromophenol blue, 0.0625M Tris-Cl pH 6.8, 5% 2-mercaptoethanol), heated at 95
o
C 
for 5-10 minutes, and kept at -20
o





Cells were washed in ice-cold PBS twice, resuspended in CF2 buffer and 
supplemented with a protease inhibitors cocktail (and a phosphatase inhibitors 
cocktail when phospho-proteins were of interest), and kept on ice for 20 minutes. The 
sample was pipetted up and down several times and was centrifuged immediately at 
10,000 xg for 10 minutes at 4
o
C. The supernatant was transferred to a new tube and 
the pellet was discarded. The NaCl concentration was adjusted to 150 mM by adding 
appropriate amounts of the CF1 buffer, the sample was quantified using the BCA 
assay (Thermo Scientific) according to the manufacturer’s recommendations. The 
sample was then mixed with SDS polyacrylamide gel electrophoresis (PAGE) sample 
buffer (2% SDS, 10% glycerol, 0.002% bromophenol blue, 0.0625M Tris-Cl pH 6.8, 
5% 2-mercaptoethanol), heated at 95
o
C for 5 minutes, and kept at -20
o
C or used 
immediately for SDS PAGE. Transfers were made onto 0.45µm nitrocellulose 
membranes. The membranes were blocked in 5% milk PBST for 1 hr at room 
temperature, and the primary and secondary antibodies were incubated at 4
o
C 
overnight and 1hr at room temperature respectively, with three 5-minute washes in 
between incubations. The membranes were subsequently scanned on an Odyssey CLx 
imager (LI-COR) and the results were analysed using the Image Studio Lite software 
version 5.2.5 (LI-COR). Antibodies used in this work are listed in Table 2.2. Note that 
all western blotting for MED23 was done using the BD biosciences anti-MED23 
antibody, unless otherwise stated. 
Table 2.2: List of antibodies used for western blots and Co-IP 
sn Target Supplier Catalogue Number Dilution 
1. Mouse MAVS Cell signalling #4983 1:500 
2. Human MAVS Santa Cruz sc-166583 1:100 
3. IkBα Cell signalling #4814S 1:500 
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4. IKKα Santa Cruz sc-7218 1:100 
5. NF-κB p65 Santa Cruz sc-8008 1:250 
6. Mouse GAPDH Ambion AM4300 1:20000 
7. Human GAPDH Protein Tech 10494-1-AP 1:20000 
8. HA Biolegend 901503 1:500 
9. Flag M2 Sigma F1804 1:2000 
10. Human IRF3 Abclonal A11373 1:250 
11. Human pIRF3 Abcam ab138449 1:500 
12. Mouse IRF3 Cell signalling #4302S 1:500 
13. Mouse pIRF3 Cell signalling #4947 1:500 
14. TBK1 Cell signalling #3013S 1:500 
15. STAT1 Abcam ab92506 1:500 
16. pSTAT1 Cell signalling 9167S 1:500 
17. ISG56 Pierce PA3-848 1:500 
18. RIG-I Santa Cruz sc-376845 1:100 
19. STING (D2P2F) Cell signalling #13647 1:500 
20. Mouse pSTING Cell signalling #72971S 1:500 
21. VF1 Abmart 4K5 1:100 
22. NS7 Non-commercial  - 1:500 
23. mCherry Source BioScience LS-C204825 1:2000 
24. GFP Sigma G1544 1:2000 
25. MED23 (HPA) Sigma (HPA) HPA070341 1:500 
26. MED23 (BD) BD biosciences 550429 1:500 
27. hnRNPI Santa Cruz sc-16547 1:250 
 
Co-immunoprecipitation 
Co-immunoprecipitation was carried out based on a protocol modified from van Essen 
et al.168 Briefly, the cells were washed in 1 ml of ice-cold PBS twice by centrifuging 
at 10,000 xg for 10 seconds at 4
o
C. The cells were then resuspended in 600 µl L2 lysis 
buffer (50 mM Tris pH8, 2 mM EDTA, 0.1% NP-40, 10% glycerol, 250 mM NaCl) 
supplemented with a protease inhibitors cocktail and kept on ice for 20 minutes. The 
sample was pipetted up and down several times and was centrifuged at 10,000 xg for 
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10 minutes at 4
o
C. The supernatant was transferred to a new tube and the pellet was 
discarded. To adjust the NaCl concentration to 150 mM, 200 µl L1 lysis buffer (50 
mM Tris pH8, 2 mM EDTA, 0.1% NP-40, 10% glycerol) was added, and 80 µl of this 
adjusted sample was transferred to a new tube as the whole cell lysate. To the 
remaining sample, 60 µl of resuspended 50% slurry of anti-FLAG M2 antibodies 
conjugated agarose beads were added and the samples were incubated on a rotator at 
4
o
C for 2 hrs. The sample was centrifuged at 300 xg for 1 minute at 4
o
C, 80 µl of the 
supernatant was transferred to a new tube as the flow through and the rest was 
discarded. The pellet was washed in 1 ml of L3 buffer (50 mM Tris pH8, 2 mM EDTA, 
0.1% NP-40, 10% glycerol, 150 mM NaCl) 4 times by centrifuging at 300 xg for 1 
minute at 894
o
C and resuspended in 80 µl of L3 buffer. The samples were then mixed 
with western blotting buffer (2% SDS, 10% glycerol, 0.002% bromophenol blue, 
0.0625M Tris-Cl pH 6.8, 5% 2-mercaptoethanol), heated at 95
o
C for 5 minutes, and 
kept at -20
o
C or used immediately for western blotting. 
 
Chromatin immunoprecipitation 
Chromatin immunoprecipitation was carried out using the Go-ChIP Protein G 
Enzymatic Kit (Biolegend), according to the manufacturer’s protocol. Briefly, 
following cell stimulation with poly (I:C), the cells were trypsinised and washed in 
PBS. Crosslinking was carried out by incubating the cells in serum-free DMEM 
containing 1% formaldehyde (Sigma) for 10 minutes at room temperature, and the 
reaction was quenched by incubating the cells in 0.65M glycine at room temperature 
for 5 minutes. The cells were lysed in the hypotonic buffer, followed by incubation of 
the nuclei in digestion buffer. After a quick DNA quantification, 1U of shearing 
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cocktail was added for every 5µg of chromatin and the sample was incubated on the 
heat block at 37
o
C for 5 minutes. The cells were then lysed in lysis buffer and the 
chromatin was aliquoted and stored at -80
o
C while shearing efficiency analysis is 
performed.  
 
After assessing shearing efficiency, 1µg of antibodies per 3µg of chromatin and the 
sample was incubated on a rotator at 4
o
C overnight. Immunoprecipitation was carried 
out with the protein G spin columns provided, followed by reverse crosslinking with 
NaHCO3 and NaCl at 65
o
C for 2 hrs. The sample was treated with proteinase K at 
37
o
C for 1 hr, and the DNA was column-purified after which it was kept at -20
o
C or 
used immediately for qPCR. 
 
The antibodies used include anti-RNA Polymerase II Antibody (Biolegend, 904003) 
and the IgG1 κ Isotype Ctrl Antibody (Biolegend, 401401). The primers used are listed 
in Table 2.3. 
Table 2.3: List of ChIP-qPCR primers 






















Atianand et. al., 
2016171 
5. IL6 promoter AGACTTCCATCCAGTTGCCT, 
CAGGTCTGTTGGGAGTGGTA 


















RNA extraction with on-column DNAse treatment were done using the GenElute 
Mammalian Total RNA Miniprep Kit (Sigma-Aldrich) according to the 
manufacturer’s protocol. Briefly, sample was lysed in 250μl of lysis buffer and kept 
on a rocker for 5 minutes. 250μl of 70% ethanol was added and mixed well, before 
transferring into the binding column. The column was centrifuged at maximum speed 
for 30 seconds and the flow through was discarded. 250μl of Wash Solution 1 was 
added and the column was centrifuged at maximum speed for 30 seconds. 50μl of 
master mix containing 1x DNAse I buffer and 1U of RNAse-free DNAse I was added 
to the column and incubated at 37
o
C for 20 minutes. 250μl of Wash Solution 1 was 
then added and the column was centrifuged at maximum speed for 30 seconds. The 
flow through was discarded and 250μl of Wash Solution 2 was added and the column 
was centrifuged at maximum speed for 30 seconds. This was repeated once, after 
which the column was placed onto a new collection tube and centrifuged at maximum 
speed for 1 minute. The column was then re-fitted with a new collection tube, and 
RNA was eluted in 50μl of PCR-grade water. RNA was quantified using the Nanodrop 
1000 (ThermoFisher Scientific) and was used immediately for downstream 






cDNA was synthesized using the M-MLV Reverse Transcriptase (Promega), 
according to the manufacturer’s protocol. Briefly, 5μl of RNA (0.5-2μg) was mixed 
with 5μl of 50μM random hexamers (Roche) and heated at 70
o
Cfor 5 minutes. The 
tube was chilled on ice for 1 minute, and 1μl of 10μM dNTPs, 5μl of 5x M-MLV 
buffer (250mM Tris-HCl (pH 8.3 at 25°C), 375mM KCl, 15mM MgCl2, 50mM DTT), 
0.5μl of RNAseOUT (20U, Invitrogen), 0.5μl of M-MLV enzyme (100U) and 8μl of 
PCR-grade water. The tube was centrifuged briefly to collect the contents at the 
bottom, incubated at 37
o
C for 1 hr and then 95
o
C for 5 minutes. The sample was then 
diluted to 90μl with PCR-grade water. 
 
qPCR was carried out using the SYBR Green mastermix containing 2.5mM MgCl2, 
400μM dNTPs, 1/10,000 SybrGreen (Molecular Probes), 1M Betaine (Sigma), 
0.05U/μl of Gold Star polymerase (Eurogentec), 1/5 10X Reaction buffer (750 mM 
Tris-HCl pH 8.8, 200 mM [NH4]2SO4, 0.1 % [v/v] Tween 20, Without MgCl2), and 
28/10,000 ROX Passive Reference buffer (Eurogentec). 5μl of sample from the cDNA 
synthesis or from the ChIP experiment was added to 0.25μl each of the forward and 
reverse primers (2.5pmol/μl final concentration), 12.5μl of the master mix and 7μl of 
PCR-grade water. Plate was centrifuged briefly to collect the contents at the bottom 
and ran on a ViiA 7 Real-Time PCR System (ThermoFisher Scientific), with a 15-
second 95
o
C denaturation step and a 1-minute 60
o
C annealing/extension step for 40 
cycles. Relative gene expression was calculated using the Livak method (ΔΔCt) 
relative to mock-transfected conditions,
172
 and normalized to a house keeping gene 
(Gapdh for all the mouse samples, and b-actin for the human samples). Primers used 
in this work are listed in Table 2.4. 
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Table 2.4: List of qPCR Primers used 

























































GGGCTGTGTTGGCCATGA (Rev. for qPCR) 




































































































































The cells were seeded on cover slips overnight and were either mock transfected or 
transfected with 1 µg/ml of poly (I:C) using Lipofectamine 2000, according to the 
manufacturer’s protocol. The cells were fixed in 4% paraformaldehyde for 15 minutes, 
washed twice with PBS, and blocked in 5% normal goat serum in PBST for 1 hr. The 
cells were then incubated with the primary antibody diluted in blocking buffer at room 
temperature for 1hr, washed 3 times with PBST for 5 minutes each, incubated with 
the secondary antibody diluted in blocking buffer at room temperature for 1hr, washed 
3 times with PBST for 5 minutes each, and then washed twice in PBS. The cover slips 
were then mounted on slides with Mowiol (Sigma) containing the DAPI nuclear stain. 
The cells were visualised on the Leica SP5 confocal microscope, and data were 




Statistical analysis and software 
Prism 6.0 (Graph Pad) was used for all statistical analysis, and one-way repeated 
measures ANOVA with Bonferroni multiple comparisons tests was applied to 
determine statistical significance, unless where indicated otherwise. In all cases, ‘ns’, 
*, **, ***, and **** are used to denote p>0.05, p≤0.05, p≤0.01, p≤0.001 and p≤0.0001 
respectively. The Image J software was used for all confocal micrograph preparation 
and Image Studio Lite 5.2 was used for western blot quantification. Clustal Omega 
was used for all sequence alignments, and Snapgene 4.2 was used for primer design 












A RIG-I/STING-dependent innate immune response pathway restricts 







MDA5 (IFIH1) was shown to play a central role in IFN induction following infection 
with both acute and persistent murine noroviruses
122,123
. However, the increase in viral 
titres observed in MNV-infected Ifih1 knockout mice and BMDCs are only moderate, 
and MNV infection is not lethal in Ifih1 knockout mice in contrast to Stat1 knockout 
mice
19,122
, indicating the potential presence of other factors that restrict viral 
replication. While studying the MNV VF1 protein, we observed that it inhibits IFN 
induction only in STING-competent cells, and we therefore hypothesized that STING 
plays a role in IFN responses against MNV. This chapter aims to (1) define the 
function of STING in the restriction of MNV1, (2) determine the receptor responsible 
for STING activation in MNV1-infected cells, and (3) clarify the mechanism of VF1 
antagonism of host IFN responses. We show that both RIG-I and STING contribute 
to a robust IFN response to infection with MNV1 in primary BMDMs and RAW264.7 
cells, with a significant increase in viral titres following infection in RIG-I- and 
STING-deficient cells. We also show that STING is non-canonically activated in 
MNV1 infected cells, in a manner that may be partly, but not completely, RIG-I-
dependent. Furthermore, our data indicate that the MNV VF1 protein binds to STING 
and can inhibit IFN induction downstream of RIG-I. Taken together, our data 
demonstrate the presence of a RIG-I/STING-dependent innate response pathway that 
restricts the replication of noroviruses, and an attempt by the murine norovirus to 






3.1. VF1 inhibits IFN induction only in STING-competent cells 
The MNV VF1 protein counteracts induction of type I IFNs through an as yet 
unknown mechanism
10,11
. A common and considerable challenge in studying the 
functions of MNV proteins, including VF1, is that primary murine macrophages and 
cell lines are often difficult to transfect
174,175
, and the transfection process itself can 
lead to induction of IFNs in them. To circumvent these limitations, we transduced two 
easy-to-transfect cell lines, HeLa M and HEK293T, with the MNV receptor 
CD300lf
24,25
. To examine whether VF1 inhibits IFN induction in human cells, the 
CD300lf-expressing HeLa M and HEK293T cells were infected with wild-type 
MNV1 or the previously described VF1-deleted mutant M1 in which a stop codon was 
introduced at position 17 of VF1 without affecting the underlying VP1 sequence
10
. 
Interestingly, whereas RAW264.7 and HeLa M cells infected with the M1 virus 
induced higher levels of IFN-β compared to cells that were infected with wild type 
MNV1, there was no significant difference in IFN-β induction in HEK293T cells 
infected with either the wild type virus or M1 (figure 3.1a). These findings suggest 
that a factor or pathway present in HeLa M and RAW264.7 cells, but absent in 
HEK293T is required for the phenotypic differences observed between cells infected 
with the wild type and M1 viruses. 
 
Both being epithelial-like cell lines, HeLa M and HEK293T cells likely express the 
same repertoire of components of the IFN response pathway, with an exception of the 
adapter protein STING that is only marginally expressed in HEK293T cells, compared 
to HeLa M cells (Burdette et al.176, and figure 3.1b). To further examine IFN induction 
in HeLa M and HEK293T cells following infection with MNV, the cells were either 
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mock-infected, or infected with wild type MNV1 or M1 at a high multiplicity of 
infection. The cells were then harvested 10 hrs post infection and the lysates were 
assessed using western blotting. As shown in figure 3.1c (right panel), there was no 
difference in the levels of phospho-IRF3 and phospho-STAT1 between the mock-
infected cells and cells infected with either wild type or M1 MNV1 in HEK293T cells. 
This contrasts with infection in HeLa cells (figure 3.1c, left panel) where a significant 
increase is seen in the levels of both phospho-IRF3 and phospho-STAT1 following 
infection with MNV1. The HEK293T cells have an intact RNA sensing pathway as 
they are able to phosphorylate IRF3 and STAT1 in response to poly (I:C) transfection 
(figure 3.1d). Taken together, these data demonstrate an attenuation of the IFN 
response to MNV1 in HEK293T cells, compared to HeLa M and RAW264.7 cells, 






Figure 3.1. VF1 inhibits IFN induction only in STING-competent cells 
(a) RAW264.7 were infected with MNV1 at an MOI of 0.01 and harvested 24hrs post-
infection, while HeLa M and HEK293T cells were infected at an MOI of 10 and 
harvested 10hrs after infection. RNA from these samples were subjected to RT-
qPCR. Data represent experiments done in triplicates, and is shown relative to mock-
infected cells and normalised to mouse Gapdh for the RAW264.7 cells, and human 
β-actin for the HeLa M and HEK293T cells. 
(b) Lysates from HeLa M and HEK293T cells were assessed by western blotting for 





































































































































(c) HeLa M and HEK293T cells were either mock-infected, or infected at an MOI of 
10 with either wild-type MNV1 or the VF1-deleted M1 mutant. The cells were 
harvested 10hrs after infection and assessed by western blotting for the indicated 
proteins. 
(d) HEK293T cells were transfected with indicated amounts of poly (I:C). The cells 




3.2. Small-molecule inhibitors of STING reduce type I IFN induction in MNV1 
infected RAW264.7 cells and BMDMs 
To explore the role of STING in the antiviral response against MNV, we made use of 
the recently described covalent small-molecule inhibitors of STING; C-176 and H-
151
177
. As shown in figure 3.2a, both drugs are able to inhibit induction of IFN-β 
following transfection of poly (dA:dT) in RAW264.7 cells, but not poly (I:C), 
consistent with previously published results. To determine whether STING is required 
for induction of IFNs following infection with MNV, RAW264.7 cells were pre-
treated with DMSO or titrated doses of C-176 or H-151, and then infected with wild 
type MNV1 at a high MOI. The cells were harvested 9 hrs post infection and subjected 
to RT-qPCR. As shown in figure 3.2b, there is a significant dose-dependent decrease 
in IFN-β induction in cells treated with either C-176 or H-151, compared to DMSO. 
These data indicate that STING is required for a robust induction of IFNs in 







To examine the role of STING in primary macrophages, bone marrow cells from 
C57BL/6 mice were differentiated into bone marrow-derived macrophages 
(BMDMs), pre-treated with either DMSO or titrated doses of C-176 or H-151 for 2 
hrs, and subsequently infected with MNV1 at a high MOI. The cells were harvested 
12 hrs post infection and subjected to RT-qPCR. As shown in figure 3.2c, and 
consistent with data from assays in RAW264.7 cells, there is a significant decrease in 
IFN-β induction in MNV-infected BMDMs following treatment with the small-
molecule inhibitors of STING in a dose-dependent manner. To determine the role of 
STING in restricting MNV1 replication, BMDMs were pre-treated with DMSO or 
titrated doses of C-176 or H-151, and then infected with MNV1. The samples were 
harvested at different time points post infection and infectious viral titres were 
determined using TCID50 in RAW264.7 cells. As shown in figure 3.2d, there is a 
significant increase in viral titres following treatment with STING inhibitors in a dose-
dependent manner. Altogether, these data indicate that STING plays an important role 







Figure 3.2. Small-molecule inhibitors of STING reduce type I IFN induction in 
MNV1-infected RAW264.7 cells and BMDMs 
(a) RAW267.4 cells pre-treated with DMSO, 0.5μM C-176 or 0.5μM H-151 for 2 hrs, 
were either mock-transfected, or transfected with 1μg poly (I:C) or poly (dA:dT). The 
cells were harvested after 2 hrs and subjected to RT-qPCR. Data represent 
experiments done in triplicates, and is shown relative to mock-transfected cells, and 
normalised to mouse Gapdh 
(b) RAW267.4 cells pre-treated with DMSO, or indicated amounts of C-176 or H-151 
for 2 hrs, were either mock-infected or infected with wild-type MNV1 at an MOI of 10. 
The cells were harvested 9 hrs post-infection and subjected to RT-qPCR. Data 
represent two independent experiments done in triplicates, and is shown relative to 
mock-infected cells, and normalised to mouse Gapdh 
(c) BMDM cells pre-treated with DMSO, or indicated amounts of C-176 or H-151 for 
2 hrs, were either mock-infected or infected with wild-type MNV1 at an MOI of 10. 
The cells were harvested 12 hrs post-infection and subjected to RT-qPCR. Data 
represent two independent experiments done in triplicates, and is shown relative to 
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(d) BMDM cells pre-treated with DMSO, or indicated amounts of C-176 (left panel) or 
H-151 (right panel) for 2 hrs, were either mock-infected or infected with wild-type 
MNV1 at an MOI of 10. The samples were harvested 12 hrs post infection and 
infectious viral titres were determined using TCID50 in RAW267.4 cells. Data 






3.3. STING depletion impairs induction of type I IFNs in MNV1-infected 
RAW264.7 cells 
To confirm the requirement for STING in the restriction of MNV, RAW264.7 cells 
were transduced with either a control shRNA (shEGFP) or shRNA targeting mouse 
STING (shSTING-3). STING knockdown was assessed by RT-qPCR and western 
blotting (figure 3.3a). The cells were then either mock transfected or transfected with 
poly (I:C) or poly (dA:dT) for 3hrs, and assessed by RT-qPCR. As shown in figure 
3.3b, the cells expressing shRNA targeting STING showed a significant reduction in 
IFN-β induction following poly (dA:dT) transfection, but not poly (I:C) as expected. 
The cells expressing shRNA targeting STING showed a significant decrease in IFN-
β induction following infection with MNV1 (figure 3.3c) at both high and low MOI, 
in keeping with data from the small-molecule inhibition experiments, with a 
corresponding increase in viral titres (figure 3.3d). Overall, these data confirm a role 





Figure 3.3. STING knockdown impairs induction of type I IFNs in MNV1-infected 
RAW264.7 cells 
(a) RAW264.7 cells stably transduced with control shRNA (shEGFP) or shRNA 
targeting mouse STING (shSTING-3) were lysed and assessed for STING mRNA via 
RT-qPCR (left panel) or analysed via western blotting (right panel). Data in the left 
panel is presented relative to control and normalised to Gapdh (n=3). 
(b) RAW264.7 cells stably transduced with control shRNA (shEGFP) or shRNA 
targeting mouse STING (shSTING-3), were mock transfected, transfected with 
1μg/ml of Poly (I:C), or with 1μg/ml of Poly (dA:dT) for 6hrs, and were subsequently 
harvested and assessed for IFN-β mRNA using RT-qPCR. Data is expressed relative 
to control and normalised to Gapdh (n=3). 
(c) and (d) RAW264.7 cells stably transduced with control shRNA (shEGFP) or 
shRNA targeting mouse STING (shSTING-3), were mock infected or infected with 
wild-type MNV1 at an MOI of 10 and 0.05, and harvested at 9 hrs and 24 hrs post 
infection, respectively. Samples were assessed for IFN-β mRNA via RT-qPCR (c), or 
infectious viral titres were determined using TCID50 in RAW264.7 cells (d). Data in 











































































































































































































3.4. STING is non-canonically activated in MNV1 infected cells partly in a RIG-I-
dependent manner 
Canonical activation of STING following sensing of foreign or mis-localised DNA is 
marked by its dimerization and phosphorylation by TBK1 (figure 3.4a), followed by 
translocation from the ER to perinuclear vesicles
57,178
. A recent study that explored 
the role of STING in the restriction of a broad range of RNA viruses noted that neither 
phosphorylation nor translocation of STING occurs following infection with VSV, 
SINV, SeV, ISVP and IAV
70
. However, in that study, even though STING was shown 
to play an important role in controlling viral infections, it did so in an IFN-independent 
manner. Studies that showed a role for STING in IFN induction following infection 
with RNA viruses, including IAV and JEV, also demonstrated STING dimerization 
and translocation
68,69
. To assess STING activation in cells infected with MNV, HeLa 
M cells expressing the MNV receptor CD300lf and BMDMs were infected with 
MNV1 at a high MOI and probed for STING phosphorylation by western blotting. As 
shown in figures 3.4b and 3.4c, there was no increase in phosphorylation of STING 
in HeLa M cells and BMDMs infected with MNV1 compared to mock-infected cells, 
suggesting that STING activation in MNV-infected cells is likely to occur in a non-
canonical manner, akin to that seen in infection with other RNA viruses as reported 
by Franz et al.70, or similar to the recently described cGAS-independent IFI16-
STING-TRAF6 pathway that induces gene expression via NF-kB following 




Next, the upstream receptor that mediates STING activation in MNV-infected cells 
was examined. Several studies in the past have linked RIG-I detection of viral RNA 
to activation of STING in cells infected with RNA viruses
66,67,69,70
. To examine the 
63 
 
role of RIG-I in IFN induction in MNV-infected cells, wild type and RIG-I-deficient 
BMDMs (figure 3.4d) were infected with MNV1 at a high MOI and harvested 12 hrs 
post infection. A significant decrease in induction of both type I and III IFNs was seen 
in the Ddx58-/- cells following MNV infection compared to Ddx58+/+ cells (figure 
3.4e), with a corresponding decrease in induction of ISGs (figure 3.4f). To determine 
if RIG-I is required for activation of STING, wild type and RIG-I-deficient BMDMs 
were infected with MNV1 following pre-treatment with either DMSO or H-151. 
Infectious viral titres were then obtained via TCID50 in RAW264.7 cells. As shown 
in figure 3.4g, there was an increase in viral titres in Ddx58 knockout cells compared 
to the wild type. Interestingly, although there was generally more virus following 
STING inhibition than there was in the wild type or Ddx58 knockout cells treated with 
DMSO, there was no difference between wild type and Ddx58 knockout cells treated 
with H-151, suggesting that RIG-I is required, albeit partly, for the STING-dependent 
restriction of MNV.  
 
Considering that the cGAS-dependent activation of STING has been implicated in 
restricting at least one other RNA virus
62,63
, the role of cGAS during MNV infection 
was explored. A small-molecule inhibitor of murine cGAS, RU.521, was recently 
described, and was shown to inhibit IFN induction downstream of the cGAS-STING 
pathway, but not in cells stimulated with synthetic 5’-triphosphorylated hairpin RNA 
or dsRNA
180,181
. However, in our hands, doses sufficient enough to show moderate 
inhibition of the cGAS-STING pathway in RAW264.7 cells also inhibited the IFN 
response to poly (I:C) (figure 3.4h). This means that although there was a significant 
decrease in IFN-β induction in MNV1-infected cells pre-treated with RU.521 (figure 
64 
 
3.4i), it is not clear whether this was due to inhibition of cGAS alone or due to an off-









































































































































































































































Figure 3.4. STING is non-canonically activated in MNV1 infected cells, partly in 
a RIG-I-dependent manner 
(a) CD300lf+ HeLa M cells were either mock-transfected or transfected with 10μg/ml 
of poly (dA:dT). The cells were harvested 3 hrs later and assessed via western 
blotting using the indicated antibodies. 
(b) and (c) CD300lf+ HeLa M cells (b) or BMDM cells (c) were either mock-infected 
or infected with wild-type MNV1 at an MOI of 10. The cells were harvested 10 hrs 
post-infection and assessed by western blotting for STING, pSTING, MNV NS7, and 
GAPDH. 
(d) Ddx58+/+ (WT) and Ddx58-/- (KO) BMDM cells were treated with 1000 U/ml of 
mouse IFN-β. The cells were harvested 4 hrs later and assessed by western 
blotting for RIG-I and GAPDH. 
(e) and (f) Ddx58+/+ (WT) and Ddx58-/- (KO) BMDM cells were either mock-infected 
or infected with wild-type MNV1 at an MOI of 10. The cells were harvested 12 hrs 
post-infection and subjected to RT-qPCR. Data represent two independent 
experiments each done in triplicates, and is shown relative to mock-transfected 
cells, and normalised to mouse Gapdh. 
(g) Ddx58+/+ (WT) and Ddx58-/- (KO) BMDM cells were either mock-infected or 
infected with wild-type MNV1 at an MOI of 10 following pre-treatment with DMSO or 
5μM H-151. The cells were harvested 12 hrs post-infection and viral titres were 
assessed by TCID50 in RAW264.7 cells (n=3). 
(h) RAW267.4 cells pre-treated with DMSO or indicated doses of RU.521 (2.5μg/ml 
and 10μg/ml for the left and right panels, respectively) for 3 hrs, were either mock-
transfected, or transfected with 1μg poly (I:C) or poly (dA:dT). The cells were 
harvested after 2 hrs and subjected to RT-qPCR. Data is shown relative to mock-
transfected cells and normalised to mouse Gapdh (n=3). 
(i) RAW267.4 cells pre-treated with DMSO, or 10μg/ml of RU.521 for 3 hrs, were 
either mock-infected or infected with wild-type MNV1 at an MOI of 10. The cells 
were harvested 9 hrs post-infection and subjected to RT-qPCR. Data is shown 
relative to mock-infected cells and normalised to mouse Gapdh (n=3). 
 
3.5. VF1 interacts with STING and inhibits induction of IFNs downstream of  
RIG-I 
Having determined that the MNV VF1 protein is only able to inhibit IFN induction in 
the presence of STING, a literature search was performed to identify viral proteins 
that are known to counteract STING, in order to determine if VF1 has any previously 
described feature utilized in counteracting STING activation and/or function. We 
66 
 
found a highly conserved LXCXE motif between amino acids 158 and 162 of VF1 
(figure 3.5a). The same motif was previously shown to mediate interactions between 
STING and the HPV E7 and AdV E1A proteins, both of which inhibit IFN induction 
downstream of STING
182
. In addition, the LXCXE motif is also present in human 
IFI16 and mouse IFI204 (p204), host proteins that interact with STING to mediate 
IFN induction following detection of DNA, although its role in this interaction has not 
been explored
183–185
. Based on this it was hypothesized that VF1 interacts with 
STING. To test this, HEK293T cells were co-transfected with Flag-VF1 and either 
HA-STING or HA-EGFP, and immunoprecipitation was carried out using agarose 
beads conjugated to anti-Flag M2 antibodies. As shown in figure 3.5b, VF1 strongly 
associated with STING, but not EGFP. Similar results were obtained with Flag-
STING and HA-VF1 (figure 3.5c), indicating an interaction between VF1 and STING. 
 
Next, the effect of VF1 over-expression on IFN induction in response to various 
ligands was explored. For this assay, HeLa M cells were transduced at a high MOI 
with lentiviruses carrying bicistronic constructs encoding either EGFP or VF1 and co-
expressing mCherry (figures 3.5d and 3.5e). After a few passages, the cells were either 
mock-transfected or transfected with poly (I:C), poly (dA:dT), or titrated amounts of 
a synthetic tri-phosphorylated hairpin RNA (3p-hpRNA) that specifically activates 
RIG-I – it should be noted that the poly (I:C) used in this work is the longer form that 
specifically activates MDA5
186
. No significant difference was observed in IFN 
expression in the presence of either VF1 or EGFP with transfection of poly (I:C) or 
poly (dAdT) (figures 3.5f and 3.5g). However, there was a significant reduction in 
both IFN-β and IFN-λ1 with the RIG-I-specific 3p-hpRNA, with a corresponding 
67 
 
reduction in viperin expression (figure 3.5h). Overall, this indicates that VF1 interacts 





























































MNV1_VF1   SLFLMCVESFG
MNV3_VF1   FPFLTCVEFFG
HPV_E7     TTDLYCYEQLN
AdV_E1A    VIDLTCHEAGF
IFI16   KLKLTCFELAP
IFI204(1)  QPKLVCGEHSF
IFI204(2)  KLRLVCFELTS


















































































































































Figure 3.5. VF1 interacts with STING and inhibits induction of IFNs 
downstream of RIG-I 
(a) An alignment of the LXCXE motifs of MNV1 VF1, MNV3 VF1, HPV E7, AdV E1A, 
IFI16, and IFI204. 
(b) and (c) Lysates from HEK293T cells co-transfected with indicated plasmids, were 
subjected to co-immunoprecipitation with anti-flag M2 antibodies-conjugated agarose 
beads, and subsequently analysed via western blotting. Data is representative of two 
independent experiments. 
(d) A schematic representation of the bi-cistronic plasmids packaged in the 
lentiviruses used.  
(e) Lysates from the EGFP- and VF1-transduced HeLa M cells were assessed via 
western blotting.  
(f) and (g) EGFP- and VF1-transduced HeLa M cells were either mock-transfected 








































harvested 6 hrs later and assessed via RT-qPCR. Data is shown relative to mock-
transfected cells and normalised to human b-actin (n=3). 
(h) EGFP- and VF1-transduced HeLa M cells were either mock-transfected or 
transfected with indicated amounts of 3p-hpRNA, harvested 6 hrs later and assessed 
via RT-qPCR. Data represent two independent experiments each done in triplicates, 
and is shown relative to mock-transfected cells and normalised to human b-actin. 





Several decades after the discovery of the human norovirus, with thousands of lives 
and billions of dollars lost, the lack of a robust cell culture system still severely 
hampers development of vaccines and therapeutics. This could be in large part as a 
result of our limited understanding of the immune responses against an infection with 
the virus
128
. In this chapter, using MNV as a surrogate model, the presence of a RIG-
I/STING-dependent innate response pathway that restricts the replication of 
noroviruses was demonstrated, and an attempt by the murine norovirus to subvert it 
through expression of an accessory protein was described.  
 
RIG-I contributes to detection of MNV 
Our data indicate that RIG-I contributes to host responses against MNV. Host cells 
detect intracellular PAMPs from RNA viruses by deploying the RIG-I-like receptors, 
a family of ubiquitously expressed soluble cytoplasmic receptors that include RIG-I, 
MDA5 and LGP2, discussed in detail in Chapter 1. While MDA5 has been established 
as a bona fide PRR in MNV-infected cells, other PRRs likely contribute since MNV 
infection is lethal in Stat1-/- mice, but not in Ifih1-/- mice. A study that explored RIG-I 
inhibition by a bacterial quorum-sensing molecule showed that while treating cells 
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with the molecule lead to a moderate increase in SeV titres in HEK293T cells, it did 
not appear to affect MNV titres in RAW264.7 cells
129
 – although it is not clear whether 
there was any effect on IFN induction by the MNV infection or if the dose used was 
sufficient. No other study published to date has looked at the role of RIG-I in sensing 
MNV infections, but it has been previously demonstrated that the murine norovirus 
polymerase is able to transcribe RNA species that can be detected by both RIG-I and 
MDA5, but not TLR-3
144
. The role of RIG-I in the restriction of human norovirus was 
also previously explored to a limited degree. There was no significant difference in 
replication following transfection of viral RNA into Huh-7 and the RIG-I-deficient 




The initial reluctance to consider RIG-I in the sensing of MNV came about partly as 
a result of data from the work on human norovirus replication in Huh-7.5 cells, and 
partly as a result of initial seminal studies on picornaviruses as they share similarities 
to caliciviruses such as the presence of VPg – thought to, among other things, protect 
the viral genome from detection by RIG-I
122
. However, it is now clear that Huh-7.5 
are not only RIG-I-deficient, but they are also deficient in STING
187,188
, and our data 
indicates that IFN responses are severely attenuated in STING-deficient HEK293T 
cells. In addition, several members of the Picornaviridae family have recently been 
shown to be restricted by RIG-I, in addition to MDA5, including FMDV, Seneca 




Our finding that RIG-I is important for the restriction of noroviruses is consistent with 
data from a study on Tulane virus, a member of the Caliciviridae family136. There, 
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RIG-I-dependent restriction was shown to be particularly required early during viral 
replication while MDA5-dependent restriction was more critical during late stages of 
replication. Also, our data indicate that IFN responses are impaired to a greater extent 
in RIG-I deficient cells than expected, which suggests that either MDA5 and RIG-I 
induce IFN in a synergistic fashion, or the absence of one affects the levels or 
functions of the other. It is also interesting that although MDA5 depletion impairs IFN 
induction in cells infected with a persistent strain of MNV (CR6), there was no 
difference in viral titres
123
. Bearing in mind our data, it is possible that RIG-I and 
MDA5 display some degree of virus strain specificity or functional redundancy. The 
recent report about the role of HOIL1 in MNV-infected cells further adds an additional 
layer of complexity to this dynamic, as HOIL1 has been shown to act as a negative 
regulator to RIG-I activation in SeV-infected cells while also positively contributing 
to IFN responses to MNV
123,142
. Additional work therefore needs to be done to discern 
the relative contributions of the two receptors in restricting noroviruses. 
 
There is currently no published data regarding the cognate PAMPs recognised by the 
PRRs in MNV-infected cells, but we can speculate on the potential ligands detected 
by either RIG-I or MDA5 (figure 3.6). The MNV genome is released less than 1 hr 
post-infection and IFN transcripts are upregulated as early as 4 hours after 
infection
2,124
. While it is therefore possible that the viral genome is detected by MDA5 
in the cytosol, it is unlikely, as proteinase K treatment prior to transfection of viral 
RNA abrogates IFN induction
122
, suggesting that viral replication is required for 
generation of PAMPs detected by the PRRs, similar to what was demonstrated for 
other RNA viruses such as IAV
189
. It is theoretically possible that MDA5 detects the 
double-stranded RNA intermediate composed of the VPg-linked positive-strand RNA 
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and the de novo-synthesized negative-stranded RNA. The negative-stranded RNA is 
likely not VPg-linked and thus may be able to activate RIG-I. Additionally, RIG-I can 
detect RNA fragments produced by RNAse L digestion of host and viral RNA
190–192
. 
Lastly both RIG-I and MDA5 may recognise RNA species transcribed by the RdRp 
from host RNA templates as already demonstrated in over-expression assays with the 
MNV RdRp, and in Semliki Fever Virus-infected cells (an Alphavirus that has a 
positive-sense single-stranded RNA viral genome akin to noroviruses)
144,193
. Further 
work is therefore warranted to identify the cognate PAMPs recognised by the PRRs 
in MNV-infected cells. 
 
STING plays a central role in MNV restriction 
In this chapter, we have shown that STING is required for a robust IFN response to 
infection with MNV1 in primary BMDMs and RAW264.7 cells, with a significant 
increase in viral titres in cells pre-treated with small-molecule inhibitors of STING 
and in STING-depleted cells. While infection of primary mouse macrophages and cell 
lines with the murine norovirus induces robust levels of IFNs and other cytokines
124
, 
Huh-7 and 293FT cells do not appear to express IFNs following transfection with the 
human norovirus RNA
118,126
. Supernatant from Huh-7 cells transfected with poly 
(I:C), but not that from cells transfected with the human norovirus RNA, was able to 
inhibit replication of transfected viral RNA, suggesting that human norovirus 
replication does not trigger an IFN response
118
. Also, transfection of human norovirus 
RNA purified from patients’ stools into 293FT cells did not induce IFNs, despite the 
presence of demonstrable viral replication
126
. Moreover, neutralisation of IFN using 
antibodies, and depletion of MAVS and IRF3 using RNA silencing, did not affect 
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viral replication. Also, cells transfected with the viral RNA were able to induce IFNs 
following infection with SeV or transfection with poly (I:C), signifying that the human 
norovirus replication did not interfere with the ability of the cells to express IFNs. 
These in vitro results are, however, inconsistent with data from studies in gnotobiotic 
pigs which show increased levels of IFNs following infection with the human 
norovirus
127
. One common factor in the Huh-7 and 293FT cells is that both cell lines 



















































Figure 3.6. Schematic representation of genome replication in MNV, indicating 




Although STING mainly functions as an adapter protein in intracellular detection of 
foreign DNA, it has been shown to play important roles in the restriction of some RNA 
viruses through various independent mechanisms (recently reviewed by Maringer et 
al.194, Aguirre et al.63, Zevini et al.57, and Ni et al.56). For example, it has been shown 
that STING can promote fusion-mediated IFN induction in cells infected with IAV in 
a manner independent of cGAS
68
. However, in cells infected with DENV, membrane 
recruitment to replication complexes leads to leakage of mitochondrial DNA that 
triggers IFN induction via STING, in a process contingent on cGAS activation
62
. 
Recently, it was also demonstrated that STING can inhibit host and viral translation 
in cells infected with a wide variety of RNA viruses in a RIG-I dependent manner
70
. 





Data suggesting a role for STING in restricting RNA viruses are as old as the 
discovery of STING itself, and the first viral proteins shown to antagonize STING 
function are in fact encoded by RNA viruses
194
. Here, the role of STING in the IFN 
responses to MNV infection was explored. STING was found to be important in the 
restriction of MNV replication, partly in a RIG-I-dependent manner. This potentially 
broadens the current MDA5/IFN-dependent-centric understanding of the innate 
immune restriction of noroviruses to one that encompasses both IFN-dependent and 
independent pathways (figure 3.7). For instance, STING can inhibit replication of 
RNA viruses via translation shutoff
70
. Since STING is itself an ISG, this could explain 
a previously described ability of type I IFNs to inhibit translation of MNV proteins 
independent of PKR
65,108
. STING is also involved in inflammasome activation 
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following detection of pathogens, and this knowledge could therefore facilitate future 
studies of the complex relationship between noroviruses and commensal 
bacteria
195,196
. Importantly, this also potentially explains the discrepancy between in 







Previous studies on the role of STING in the innate response to RNA viruses 
(summarised in table 3.1) fall into two groups; (1) the ones that show canonical 






















Previous model New model
Figure 3.7. Innate immune restriction of noroviruses 
A schematic representation of our current understanding of the innate 
immune responses against noroviruses. Dotted lines indicate areas 
where there is currently no direct evidence. 
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studies in this area
57,69,184,197
; and (2) the recent screen of a broad range of RNA viruses 
that failed to observe canonical activation of STING or any reduction of IFN induction 
following STING depletion, while also demonstrating the contribution of STING in 
antiviral responses via translation inhibition
70
. Our data appear to fall in the middle, 
in that STING contributes to IFN responses to MNV, although there was no evidence 
of its canonical activation in MNV-infected cells. Nevertheless, our data contributes 
to this discussion, and suggest the need for further work in this area. 
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VF1 binds to STING and inhibits RIG-I signalling 
Lastly, VF1 was found to bind to STING and inhibit IFN induction downstream of 
RIG-I, highlighting the relevance of the RIG-I/STING pathway in restricting 
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replication of noroviruses. Given that VF1 is only expressed by the murine norovirus, 
but not the human norovirus, further work is required to determine the existence of 
additional attempts by noroviruses to counteract this pathway. The presence of the 
LXCXE motif in VF1 is also interesting, as it potentially points to a common STING-
binding motif that can be exploited by viruses and other pathogens. Although 
originally described as the Rb-binding motif, the nuclear and cytoplasmic localisation 
of STING and the Rb protein, respectively, physically compartmentalizes binding 


















Work done by Griffiths and colleagues alluded to a role for MED23, a tail subunit of 
the Mediator complex, in the specific induction of type III IFNs (discussed in greater 
detail in chapters 1)
78
. MED23 was among the main hits obtained following genome-
wide RNAi screens for host factors that inhibit replication of Herpes Simplex Virus 
type 1 (HSV1). Increased expression of type III IFNs was observed upon 
overexpression of MED23 in A549 cells, with a decrease in viral replication following 
infection with HSV1. Depletion of MED23 on the other hand, using a siRNA pool, 
lead to an increase in viral titres and a decrease in the induction of type III IFNs. 
Further mechanistic work demonstrated an interaction between MED23 and IRF7. 
Based on these findings, they concluded that MED23 specifically regulates induction 
of type III IFNs following infection with HSV1. 
 
Confocal micrographs from the Human Protein Atlas (HPA)
201
 and insilico analysis 
of the MED23 protein sequence suggest a possible presence of the human MED23 at 
peroxisomes, which could account for the role of MED23 in type III IFN responses. 
As discussed in detail in chapter 1, peroxisomal MAVS mediates a predominantly 
type III IFN response following infection by RNA viruses. We therefore hypothesized 
that MED23 localizes to both the nucleus and peroxisomes and contributes to IFN 
induction at peroxisomes. The aims of this chapter are to; (1) examine the possible 
localisation of MED23 to peroxisomes; and (2) determine the relevance of any such 




4.1. Evidence suggesting a potential peroxisomal localization for MED23 
Confocal micrographs from the Human Protein Atlas (HPA) project indicate the 
presence of an extranuclear MED23 in different human cell lines (figure 4.1a). This 
extra-nuclear MED23 has a flecked appearance within the cytoplasm that suggests 
localisation to small vesicular organelles such as peroxisomes.  
 
Bioinformatic analysis of the human MED23 sequence also indicated the presence of 
an SKM motif, a PTS1 peroxisomal targeting signal, 30 amino acids away from the 
carboxyl-terminus (figure 4.1b). The SKM motif is present in 4 out the 6 MED23 
isotypes, and is conserved humans, mice and rats (figures 4.1c and 4.1d). Although 
PTS1 motifs are typically present as the last three amino acids at the carboxyl-terminal 
end peroxisomal proteins, there are a few exceptions. The ATM protein, for example, 
was recently shown to also localize to peroxisomes, in addition to its nuclear 
localisation, via a PTS1 positioned 9 amino acids away from the carboxyl terminal 
end of the protein. Taken together, these data suggest that MED23 has a cytosolic 









Figure 4.1. Evidence suggesting a potential peroxisomal localization for 
MED23 
a) Confocal images archived from the HPA website201,202. Blue represents DAPI, 
green represents MED23, and red represents microtubules. 
[ https://www.proteinatlas.org/ENSG00000112282-MED23/cell] 
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Zebrafish        QVERII----CSLRPAMRLRLRFITHISKMEPAAVPVSNSSSVQQTSS-ASSPTAQS-TA 
Frog             QVEKII----CNLRPALKLRLRHITHISTE-SAAPPPPPMNSGSPA-------PQPN-QV 
Human            QVEKII----CNLKPALKLRLRFITHISKMEPAAVPPQAMNSGSPA-------PQSN-QV 
Mouse            QVEKII----CNLKPALKLRLRFITHISKMEPA-VPPQALNSGSPA-------PQSN-QV 
Rat              QVEKII----CNLKPALKLRLRFITHISKMEPA-VPPQALSSGSPA-------PQAN-QV 












b) A schematic representation of human MED23, showing the last 40 c-terminal 
amino acids. The predicted PTS1 targeting sequence is underlined and coloured red. 
N, n-terminal; C, c-terminal. 
c) An alignment of c-terminal sequences from the 6 MED23 isoforms available in 
UNIPROT. The predicted PTS1 targeting sequence is highlighted yellow. 
d) An alignment of c-terminal sequences of MED23 from the indicated species. The 




4.2. Confocal imaging and fractionation studies  
To examine the potential localisation of MED23 to peroxisomes, HeLa M cells 
engineered to express a peroxisome-targeted mCherry (mCherry-PTS1 HeLa) were 
used so that the mCherry served as a peroxisomal marker. Wild-type HeLa M cells or 
the mCherry-PTS1 HeLa cells were fixed, permeabilised and stained for MED23 
using the HPA anti-MED23 antibody. As shown in figure 4.2a, MED23 colocalized 
with the peroxisomal marker, suggesting that MED23 localises to peroxisomes. 
Similar results were seen in HEK293T cells stably transduced with the peroxisome-
targeted mCherry (figure 4.2b). However, in both HeLa and HEK293T cells the 
MED23 staining appeared to be mostly extra-nuclear, in contrast to previously 
described primarily nuclear localisation. To further clarify this, MED23 localisation 
was examined using a cell fractionation approach in A549 cells. For this assay, a 
western blot-validated antibody obtained from BD biosciences was used. GAPDH and 
hnRNP1 where used as controls for cytosolic and nuclear proteins, respectively. As 
shown in figure 4.2c, MED23 was found to be primarily nuclear, in keeping with data 
from previously published studies. While a small proportion is present in the cytosolic 
fraction, a proportion of hnRNP1 was also present in the cytoplasmic fraction, 




4.2. Confocal imaging and fractionation studies  
a) Confocal micrographs of WT HeLa cells (top panel) or cells stably expressing a 
peroxisome-targeted mCherry (PTS1, bottom panel), stained with the HPA anti-
MED23 primary antibody. Blue represents DAPI, green represents MED23, and red 
represents PTS1. 
b) Confocal micrographs of HEK293T cells stably expressing a peroxisome-targeted 
mCherry (PTS1), stained with the an anti-TOM20 or HPA anti-MED23 primary 
antibody. Blue represents DAPI, green represents TOM20/MED23, and red 
represents PTS1. 
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4.3. MED23 knockdown with siRNA 
The results from figures 4.1b and 4.1c above appear to contradict each other, with 
confocal imaging in HeLa and HEK293T cells indicating a predominance of 
peroxisomal MED23 while fractionation in A549 cells shows predominant nuclear 
localisation. One possible explanation could be a cell line-specific difference in 
MED23 localisation, for instance due to a preponderance of different isotypes in the 
3 cell lines.  A more likely explanation is however differences in antibody specificity 
between the HPA and the BD anti-MED23 antibodies. To examine the latter 
possibility, A549 cells were transfected with either a control siRNA (siGFP) or siRNA 
targeting MED23. Lysates from these cells were then probed for MED23 by western 
blotting, using either the HPA antibody or the BD antibody. The most prominent band 
present on the BD antibody blot was 130kDa, similar to the reported size for MED23 
(figure 4.3a). Moreover, the intensity of the 130kDa band was considerably reduced 
in cells transfected with the MED23-targeted siRNA, indicating that this was indeed 
MED23. While a similar 130kDa band was seen in the HPA antibody blot (figure 
4.3b), the band with the highest intensity was seen to be about 90kDa. This 90kDa 
band also appears to be unaffected by siRNA targeting MED23, although the siRNA 
used in this work is complementary to a sequence at the carboxyl-terminus of the 
mRNA, and MED23 isotypes with alternate residues or truncations affecting this site 
will therefore not be depleted. 
 
Confocal imaging on HeLa cells stained with the BD anti-MED23 antibody showed a 
primarily nuclear localisation, with no colocalization with the peroxisomal marker 
(figure 4.3c). Taken together, these results suggest that the HPA antibody either binds 
85 
 
to an artefactual target with a higher specificity than MED23, or to a 90kDa isotype 
of MED23 that localizes to peroxisomes. 
 
Figure 4.3. MED23 knockdown with siRNA 
A549 cells were transfected with either control siRNA (siEGFP), or siRNA targeting 
human MED23. The cells were harvested 48 hrs later, and assessed via western 
blotting using the BD Biosciences anti-MED23 antibody (a), or the HPA antibody (b). 
c) Confocal micrographs of HeLa cells stably expressing a peroxisome-targeted 
mCherry (PTS1), with either no primary antibody staining (‘secondary’ alone), or 
stained with the BD biosciences anti-MED23 primary antibody. Blue represents DAPI, 


















































4.4. Colocalization studies with MED23 overexpression 
Sequences for 6 human MED23 isotypes are currently available at Uniprot, an online 
database that curates protein sequences and functional data (schematically represented 
in figure 4.4a). Isotype 1 represents the canonical MED23 sequence and has a 
predicted size of 130kDa. Isotypes 3, 4 and 5 also have predicted sizes of about 
130kDa but differ from each other and the main isotype (isotype 1) by the presence of 
alternative residues at their carboxyl-termini. In addition, isotype 3 also has an 
additional sequence within the site that was used as the immunogen for the HPA 
antibody. Both isotypes 2 and 6 appear truncated, with predicted sizes of 100kDa and 
55kDa, respectively. Isotype 6 also has an SKL motif close to its carboxyl-terminus. 
To determine whether the prominent band seen in the HPA antibody blots represents 
any of these isotypes, isotypes 1, 2 and 6 were cloned into expression plasmids with 
EGFP tagged to their amino-termini. Isotype 2 was chosen because of its predicted 
size and the presence of the additional residues within the HPA antibody immunogen 
site that could alter its specificity. Isotype 6 was chosen because of the presence of the 
SKL motif near its carboxyl-terminus that could potentially increase the possibility of 
its localising to peroxisomes, and isotype 1 was chosen as a control. The cloned 
plasmids were transiently expressed in mCherry-PTS1 HeLa cells and the cells were 
subsequently processed for confocal microscopy. As shown in figure 4.4b, Isoform 1 
mostly localized to the nucleus, while isoforms 2 and 6 both appear to have a diffused 
cytosolic distribution. None of the isotypes showed the characteristic punctate 
peroxisomal pattern, nor did they colocalize with the peroxisomal marker, indicating 





Figure 4.4. Colocalization studies with MED23 overexpression 
a) A schematic representation of the six human MED23 isoforms, with color-coding 
indication alternative residues, predicted PTS1 targeting sites and sites of the HPA 
antibogy immunogen. Red arrows indicate isoforms selected for overexpression in 
(b). 
b) Confocal micrographs of HeLa cells stably expressing a peroxisome-targeted 
mCherry (PTS1), and transfected with EGFP, EGFP-MED23 isoform 1, EGFP-
MED23 isoform 2, EGFP-MED23 isoform 6, or none (mock). Blue represents DAPI, 
green represents EGFP, and red represents PTS1.  
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4.5. Co-expression of MED23 and differentially-localizing MAVS 
MED23 has been shown to specifically promote induction of type III IFNs, likely in 
an IRF7-dependent manner. Interestingly, while over-expression of MED23 alone in 
A549 cells did not lead to induction of IFNs in our hands, co-expression with IRF7 
lead to an increase in the induction of both IFN-λ1 and IFN-β compared to over-
expression of IRF7 alone (figure 4.5a). Similarly, co-expression of MED23 with 
MAVS lead to an increase in both IFN-λ1 and IFN-β (figure 4.5b). 
 
Activation of MAVS present on peroxisomes leads to a predominantly type III IFN 
response. If MED23 is present at peroxisomes and specifically augments type III IFN 
induction, then co-expression with a peroxisome-targeted MAVS will preferentially 
lead to induction of type III IFNs. To test this, an epitope-tagged MAVS localising to 
the peroxisomes was generated by replacing its transmembrane domain with the 
peroxisomal targeting sequence of Pex13 (figure 4.5c and 4.5d) and co-expressed with 
MED23 in A549 cells. As shown in figure 4.5e, there was a marginal increase in both 
IFN-λ1 and IFN-β following co-expression of MED23 and peroxisomal MAVS, 
similar to that seen with wild-type MAVS, indicating that MED23 does to specifically 








Figure 4.5. MED23 potentiates interferon induction independent of MAVS 
localization 
a) A549 cells transiently transfected with the pRLTK plasmid, either the empty vector 
or mouse MED23, either a control plasmid or IRF7, and either the IFNβ-luciferase 
(left panel) or the IFNλ1-luciferase (right panel) plasmids. Cells were harvested after 
24 hrs, and assessed for Firefly and Renilla luciferase. Data represent two 
independent experiments each done in triplicates, and is expressed as Firefly 
luciferase relative to control, normalised to Renilla luciferase. 
b) Similar to (a), but with MAVS instead of IRF7. 
c) A schematic representation of the plasmids encoding differentially localising MAVS 
mutants. EV, empty vector; WT, wild type; Cyto, cytosolic; Pex, peroxisomal. 
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d) Confocal micrographs of HeLa cells transiently transfected with plasmids from 
figure 4.5c above. 
e) Mavs-/- MEF cells transiently transfected with the pRLTK plasmid, either the empty 
vector or mouse MED23, one of the plasmids represented in (c) above, and either 
the IFNβ-luciferase (top panel) or the IFNλ1-luciferase (bottom panel) plasmids. Cells 
were harvested after 24 hrs, and assessed for Firefly and Renilla luciferase. Data is 
pooled from three independent experiments each done in triplicates, and is 
expressed as Firefly luciferase relative to control, normalised to Renilla luciferase. 
 
Discussion. 
In this chapter, we have explored the possible localisation of MED23 to peroxisomes. 
While initial data obtained using the HPA anti-MED23 antibody indicated extra-
nuclear nuclear localisation of Med23, we have failed to show that using an antibody 
from a different source or by over-expression of MED23 isoforms in cell lines. 
Moreover, functional data using peroxisome-targeted MAVS mutants did not support 
our hypothesis. It is therefore possible that the HPA antibody in fact detects another 
protein that localises to peroxisomes, in addition to MED23. This highlights the 
continuing need to validate antibodies prior to use for hypothesis-based scientific 
studies, especially since ‘bad antibodies’ are among the commonest causes of 
reproducibility problems in many labs
203–205
. Ironically, the HPA consortium was 




The overall aim of the work in this chapter was to determine how the host is able to 
switch between induction of one type of IFN to another are yet to be determined. 
Interestingly, our data suggests that MED23 may potentiate the induction of both type 
I and type III IFNs. In the next chapter, we examine this further and determine the 










MED23 mediates induction of target genes 







The interferon (IFN) response is among the earliest and most critical lines of defence 
against viruses
31
. Host cells have a myriad of soluble and membrane-bound pattern 
recognition receptors that can detect virus-specific ligands or perturbations from 
damage of infected cells, and are able to kickstart various molecular cascades that 
eventually lead to induction of interferons.
31
 As both types I and III IFNs play essential 
non-redundant roles in host restriction of viruses, there has been considerable interest 
in the mechanism for the host’s ability to differentially induce IFN subtypes
74,97
. 
Earlier studies have emphasized the requirement for activation of all three groups of 
transcription factors, including the IFN Regulatory Factors (IRFs), NF-kB, and AP-1 
that form the ‘IFN enhanceosome’, in order to have a robust induction of IFNs.
206,207
 
While this is still largely true, recent studies have elucidated a differential requirement 
for transcription factor activation between type I and type III IFNs. Induction of IFN-
b, for example, has been shown to depend more on activation of IRF3, while a robust 
induction of IFN-l depends more on activation of NF-kB and to some extent IRF1 
and IRF7, than it does on IRF3
73–77
. Additionally, activation of MAVS located on 
mitochondria has been shown to induce a largely type I IFN response, while activation 
of MAVS at peroxisomes induces a predominantly type III IFN response
50,53
. 
Nevertheless, the details of how the host is able to switch between induction of one 
type of IFN to another are yet to be determined. 
 
Work done by Griffiths and colleagues alluded to a role for MED23, a tail subunit of 
the Mediator complex, in the specific induction of type III IFNs (discussed in greater 
detail in chapters 1 and 4)
78
. Our data from the previous chapter indicated that MED23 
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potentiates activation of both type I and type III IFNs. We therefore hypothesized that 
MED23 plays a role in the induction of not only type III IFNs as previously reported, 
but also in the induction of type I IFNs. The aims of this chapter are to; (1) determine 
the role of MED23 in type I IFN induction; and (2) examine the mechanism of any 
such role. We show that depletion of MED23 leads to a reduction in expression of 
both type I and type III IFNs in human and mouse cell lines. We also show that Med23-
/-
 cells undergo genetic compensation, suggesting a critical role for MED23 in this 
pathway. Mechanistically, we show that MED23 interacts with IRF3, and is required 
for recruitment of the RNA polymerase (Pol) II to promoters of IRF3-dependent 
genes. Altogether, our data indicate that MED23 plays an essential role in antiviral 
responses by coupling IRF3 activation and RNA Pol II recruitment. 
 
Results 
5.1. Human and mouse cells deficient in MED23 show impaired induction of both 
type I and type III IFNs. 
Previous work done by Griffiths et al. has demonstrated that MED23 plays a role in 
the induction of type III IFNs, likely through an interaction with IRF7.
78
 However, 
while replicating their work, it was observed that whereas overexpressing MED23 
alone in A549 cells did not lead to induction of IFN-b or IFN-l1 promoter-driven 
luciferase in our hands, co-expression of MED23 with either IRF7 or MAVS lead to 
an increased induction of both IFN-b and IFN-l1, compared to an empty vector, (as 
shown in the previous chapter, figures 4.7a and 4.7b), suggesting that MED23 
potentiates induction of both type I and type III IFNs. MED23 depletion by siRNA 
also lead to a decrease in both IFN-b and IFN-l1 induction (figure 5.1a). To confirm 
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this, 3 different shRNAs targeting human MED23 were used to stably knockdown 
expression in A549 cells, as shown in figure 5.1b. Using these cells, IFN induction in 
the absence of MED23 was examined. A549 cells lacking MED23 showed a marked 
reduction in their ability to induce IFN-b and all 3 IFN-l subunits following 
stimulation with poly (I:C) (figure 5.1c). Compared with controls, MED23-deficient 
cells also showed reduced ability to induce both types I and III IFNs following 
infection with EMCV (Figure 5.1d) and stimulation with poly (dA:dT) (Figure 5.1e). 
Significantly higher levels of viral RNA were also seen in cells expressing lower 
levels of MED23, compared with controls (Figure 5.1d). Altogether, these data 
indicate that MED23 is required for the induction of both types I and III IFNs. Its 
worthy of note, that EMCV was used in these experiments as a model RNA virus, 
since the cells do not express the MNV receptor. 
 
The mammalian Mediator complex is highly conserved.
208,209
 It was therefore 
hypothesized that the requirement for MED23 in the induction of IFNs is conserved 
as well. To test this, MEF cells were stably transduced with 2 different shRNA 
targeting mouse MED23 (Figure 5.1f). A significant reduction was seen in the levels 
of IFN induced in cells lacking MED23 compared with expressing control shRNA, 
following stimulation with poly (I:C) (figure 5.1g). Together, this shows that MED23 






























































































































































































































































































































































































































































Figure 5.1 Human and mouse cells deficient in MED23 show impaired induction 
of both type I and type III interferons. 
a) A549 cells transfected with control siRNA (siGFP) or siRNA targeting human 
MED23 (si23-1) were lysed and assessed for MED23 via western blotting (left panel), 
or transfected with 1µg/ml of poly (I:C) for 6 hrs and assessed by RT-qPCR (middle 
and right panels). Data in the middle and right panels are expressed relative to control 
and normalised to β-actin (n=3).  
b) A549 cells stably transduced with control shRNA (shEGFP) or different shRNA 
targeting human MED23 (sh23-6, sh23-8, or sh23-9) were lysed and assessed for 
MED23 mRNA via RT-qPCR (left panel) or analysed via western blotting (right panel). 
Data in the left panel is expressed relative to control and normalised to β-actin (n=3). 
c) A549 cells stably transduced with different shRNA, as indicated in (a) above, were 
transfected with 0, 10, 50, or 100 ng/ml of Poly (I:C) for 6hrs, and were subsequently 
harvested and assessed for IFN-β or IFN-λ mRNA. Data is expressed relative to 
control and normalised to β-actin (n=3). 
d) A549 cells stably transduced with different shRNA, as indicated in (a) above, were 
seeded overnight and were then either mock infected or infected with EMCV at an 
MOI of 5. The cells were harvested 12 hrs post-infection, and assessed for IFN-β or 
IFN-λ1 mRNA, EMCV viral RNA. Data for IFN-β and IFN-λ1 mRNA is expressed 
relative to control, and normalised to β-actin. nd, not detected (n=3). 
e) A549 cells stably transduced with control shRNA (shEGFP) or shRNA targeting 
human MED23 (sh23-9), were transfected with 50ng/ml of Poly (dA:dT) for 6hrs, and 
were subsequently harvested and assessed for IFN-β or IFN-λ1 mRNA. Data is 
expressed relative to control, and normalised to β-actin (n=3). 
f) MEF cells stably transduced with control shRNA (shEGFP) or 2 different shRNA 
targeting mouse MED23 (sh23-1 or sh23-3) were lysed and assessed for MED23 
mRNA via RT-qPCR. Data is expressed relative to control, and normalised to Gapdh 
(n=3). 
g) MEF cells stably transduced with different shRNA, as indicated in (e) above, were 
transfected with 1 µg/ml of Poly (I:C) for 6hrs, and were subsequently harvested and 
assessed for IFN-β or IFN-λ1 mRNA. Data is expressed relative to control, and 








5.2. MED23 knock down impairs induction of IRF3- but not NF-kB-dependent 
genes 
Robust induction of type I IFNs is dependent upon a concerted interplay of activated 
transcription factors, most notably IRF3 and NF-kB
31
. We therefore hypothesized that 
MED23 is required for gene induction downstream of activated IRF3 and NF-kB. 
Indeed, A549 cells deficient in MED23 showed a marked reduction in Viperin and 
ISG15 induction in a dose-dependent manner, both of which are IRF3-dependent 
genes (Figure 5.2a). In contrast, cells lacking MED23 mostly showed higher induction 
of IL-6 and TNF-a (Figure 5.2a) when compared with controls, both of which are 
typically induced via NF-kB. A similar pattern was seen in MEF cells lacking MED23 
(Figure 5.2b).  
 
To further clarify the effect of MED23 knockdown on NF-kB-induced transcription, 
A549 cells and MEFs expressing shRNA targeting EGFP or MED23 were transfected 
with a plasmid encoding luciferase under the control of NF-kB, the control pRL-TK 
plasmid, and either an empty vector or FLAG-p65. As shown in figures 5.2c and 5.2d, 
no significant difference was seen with the shRNA targeting MED23 in A549 cells, 
with marginal increase seen in the MEFs, compared to the control shRNA. Together, 
these data suggest that MED23 is required for gene induction downstream of IRF3, 








Figure 5.2 MED23 knock down impairs induction of IRF3- but not NF-kB-
dependent genes 
a) A549 cells stably transduced with control shRNA (shEGFP) or different shRNA 
targeting human MED23 (sh23-6, sh23-8, or sh23-9), were transfected with 0, 10, 50, 
or 100 ng/ml of Poly (I:C) for 6hrs, and were subsequently harvested and assessed 
for Viperin, ISG15, IL-6, or TNFα mRNA. Data is expressed relative to control and 
normalised to β-actin (n=3). 
b) MEF cells stably transduced with control shRNA (shEGFP) or 2 different shRNA 
targeting mouse MED23 (sh23-1 or sh23-3), were transfected with 1 µg/ml of Poly 
(I:C) for 6hrs, and were subsequently harvested and assessed for Viperin and IL-6 
mRNA. Data is expressed relative to control, and normalised to Gapdh (n=3) 
c) and d) A549 cells (c) and MEFs (d) expressing shRNA targeting EGFP or MED23 
were transfected with a plasmid encoding luciferase under the control of NF-kB, the 
control pRL-TK plasmid, and either an empty vector or FLAG-p65. The cells were 
harvested after 24 hrs and assessed for Firefly and Renilla luciferase. Data is 
expressed as Firefly luciferase relative to control and normalised to Renilla luciferase. 
























































































































































































































5.3. MED23 is not required for signalling downstream of IFNAR receptors 
A previous study has suggested a role for MED23 in promoting signalling downstream 
of IFNAR receptors
210
. Ectopic expression of MED23 lead to a higher induction of a 
JAK-STAT-dependent luciferase promoter following treatment with IFN-a, 
compared to a control vector. Additionally, members of the IRF superfamily often 
have similar consensus DNA-binding sites, and activated forms of both IRF3 and 
IRF9 (via ISGF-3) are able to induce the same genes, such as in the case of RSAD2, 
ISG56 and ISG15
211–213
. To investigate whether the requirement of MED23 for gene 
induction is shared by IRF9, A549 cells stably expressing a control shRNA targeting 
EGFP or shRNA targeting human MED23 were either mock treated or treated with 
500 U/ml of recombinant human IFN-a2. The cells were harvested after 6 hrs and 
subjected to RT-qPCR. As shown in figure 5.3a, both the cells expressing the control 
shRNA and those expressing shRNA targeting MED23 show induction of viperin and 
ISG15 to similar levels. This is further confirmed via western blotting (figure 5.3b) 
with knockdown of MED23 showing no impairment in either phosphorylation of 
STAT1 or ISG upregulation (RIG-I and ISG56) following treatment with IFN-a2, 








Figure 5.3 MED23 is not required for signalling downstream of IFNAR receptors 
a) A549 cells stably transduced with control shRNA (shEGFP) or shRNA targeting 
human MED23 (sh23-9), were treated with DMEM (‘untreated’) or with 500 U/ml of 
recombinant human IFNα2 for 6hrs, and were subsequently harvested and assessed 
for Viperin and ISG15 mRNA. Data is expressed relative to control and normalised to 
β-actin (n=3). 
b) A549 cells stably transduced with control shRNA (shEGFP) or shRNA targeting 
human MED23 (sh23-9), were treated with DMEM (‘untreated’) or with 1000 U/ml of 
recombinant human IFNα2 for 6hrs, and were subsequently harvested and assessed 
for indicated proteins by western blotting. 
 
 
5.4. MEFs from MED23 null mice show evidence of genetic compensation  
To investigate whether MED23 is essential in the induction of IFNs, wild type and 
Med23-/- MEF cells (figure 5.4a, previously described160,161) were either mock 
transfected or transfected with poly (I:C) over 6hrs and the IFN expression was 
assessed. Med23-/- MEF cells stimulated with poly (I:C) showed significantly higher 
induction of both type I and type III IFNs compared to wild type cells, contrary to data 
















































































A similar mismatch between results from gene knockout and knockdown experiments 
has been previously described for several genes, and is thought to occur as a result of 
transcriptional adaptation
214,215
. This often involves upregulation of genes in other 
parts of a pathway, the effect of which is to restore the overall functionality of the 
pathway. To examine whether this is also true for MED23, RNA from unstimulated 
wild type and Med23-/- MEF cells where assessed via RT-qPCR for IRF3, p65, TBK1, 
IKKb, and MAVS. As shown in Figure 5.4c, Med23-/- cells expressed higher levels of 
all the genes assessed compared to the wild type cells. The protein levels of both IRF3 
and NF-kB were also higher in Med23-/- cells (Figure 5.4d). Altogether, these data 
suggest that MEFs from Med23 null mice undergo genetic compensation. 
 
The lack of correlation in the data obtained from RNA silencing and gene knockout 
studies could also be explained by off-target effects of the RNA silencing, although 
multiple shRNAs are unlikely to have a common off-target effect. Alternatively, it can 
be explained by the partial deletion of a gene that is able to function even in the 
absence of the wild type gene. To investigate these, Med23-/- MEF cells stably 
transduced with 2 different shRNA targeting mouse Med23 were either mock 
transfected or transfected with poly (I:C) over 6hrs and the impact on IFN induction 
was assessed. A reduction in the levels of IFNs compared to the controls will indicate 
a potential off-target effect shared by all three shRNAs or a possible functional null 
allele. As shown in Figure 5.4f, this is not the case. Together, these data indicate that 
cells from Med23 knockout mice undergo transcriptional adaptation to functionally 
































































































































































































Figure 5.4 MEFs from MED23 null mice show evidence of genetic compensation  
a) Med23+/+ and Med23-/- MEF cells were harvested and assessed for Gapdh or 
Med23 mRNA via end point PCR.  
b) Med23+/+ and Med23-/- MEF cells were transfected with 1 µg/ml of Poly (I:C) for 
6hrs, and were subsequently harvested and assessed for IFN-β or IFN-λ2 mRNA. 
Data is expressed relative to control, and normalised to Gapdh (n=3) 
c) Med23+/+ and Med23-/- MEF cells were harvested and assessed for Med23, Irf3, 
p65, Tbk1, Ikkb, or Mavs mRNA via RT-qPCR. Data is expressed relative to WT cells 
and normalised to Gapdh (n=3). 
d) Lysates from Med23+/+ and Med23-/- MEF cells were blotted for IRF3, p65 and 
GAPDH (left panel). Data in the left panel is representative of 3 independent 
experiments, and those in the right panel represent quantification from 3 different 
blots each. 
e) Med23-/- MEF cells stably transduced with control shRNA (shEGFP) or 2 different 
shRNA targeting mouse Med23 (sh23-1 or sh23-3), were transfected with 1 µg/ml of 
Poly (I:C) for 6hrs, and were subsequently harvested and assessed for IFNβ and 




5.5. MED23 is not required for activation of IRF3 
Following detection of viral RNA or DNA in the cytosol, IRF3 is recruited to and is 
phosphorylated by TBK1/IKKe, after which it dimerises and translocates into the 
nucleus to induce IFN expression
216
. Activation of NF-kB instead requires 
phosphorylation (and eventual degradation) of IkB, allowing the NF-kB heterodimer 
to translocate into the nucleus and effect gene expression. To determine whether 
MED23 is involved in activation of IRF3 and/or NF-kB, A549 cells expressing either 
shEGFP or shMED23 were transfected poly (I:C), harvested 6 hrs later and assessed 
for phosphorylation of IRF3 and degradation of IkBa by western blotting. As shown 
in Figure 5.5a, there was no difference observed in the level of phosphorylated IRF3 
between cells expressing MED23-targeting shRNA compared to the control shRNA. 
Similar results were obtained with siRNA knockdown of MED23, as shown in figures 
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5.5b and 5.5c. Translocation of IRF3 and NF-kB also appear to occur unhindered by 
MED23 depletion in cells transfected with poly (I:C) (figure 5.5d), indicating that 





























































































Figure 5.5 MED23 is not required for activation of IRF3 
a) A549 cells stably transduced with control shRNA (shEGFP) or shRNA targeting 
human MED23 (sh23-9), were either mock transfected, or transfected with 1 µg/ml of 
poly (I:C), harvested 6 hrs later, and  assessed via western blotting. 
b) A549 cells were transfected with either control siRNA (siEGFP), or siRNA targeting 
human MED23. Forty-eight hrs later, the cells were either mock transfected, or 
transfected with 10 µg/ml of poly (I:C), harvested 6 hrs later, and  assessed via 
western blotting. 
c) A549 cells were transfected with either control siRNA (siEGFP), or siRNA targeting 
human MED23. Forty-eight hrs later, the cells were treated with either DMEM or 40 
ng/ml recombinant human TNFα, harvested 6 hrs later, and  assessed via western 
blotting. 
d) A549 cells stably transduced with control shRNA (shEGFP) or shRNA targeting 
human MED23 (sh23-9), were either mock transfected, or transfected with 1 µg/ml of 





5.6. MED23 interacts with activated IRF3 and is required for recruitment of RNA 
Pol II to promoters of IRF3-dependent genes 
Gene-specific transcription factors often recruit the Mediator complex to gene 
enhancer regions via an interaction with a tail subunit of the complex
79
. It was 
therefore hypothesized that IRF3 interacts with MED23. To test this, HEK293T cells 
were co-transfected with HA-MED23 and either FLAG-EGFP or a FLAG-tagged 
constitutively-active IRF3 (IRF3-5D). The cells were then either mock-transfected or 
transfected with poly (I:C) 48 hrs later. The cells were harvested 6hrs later and co-
immunoprecipitated using anti-FLAG antibodies-conjugated agarose beads and 
analysed by western blotting. As shown in Figure 5.6a, MED23 strongly associates 




Next, the role of MED23 in the recruitment of RNA Pol II to transcription sites of 
IRF3-dependent genes was explored. A549 cells expressing either control shRNA or 
shRNA targeting MED23 were transfected with poly (I:C) and subjected to chromatin 
immunoprecipitation using anti-RNA Pol II antibodies. Immunoprecipitated DNA 
was then assessed by RT-qPCR. As shown in figure 5.6b, there was a significant 
reduction in RNA Pol II enrichment at the IFN-b promoter in MED23-depleted cells, 
indicating that MED23 is required for RNA Pol II recruitment downstream of 
activated IRF3.  
 
 
Figure 5.6 MED23 interacts with activated IRF3 and is required for recruitment 
of RNA Pol II to promoters of IRF3-dependent genes 
a) HEK293T cells were co-transfected with HA-MED23 and either Flag-EGFP or 
Flag-IRF3-5D, and after 48 hrs nuclear fractions were subjected to co-
immunoprecipitation with anti-flag M2 antibodies-conjugated agarose beads, and 























































b) A549 cells stably transduced with control shRNA (shEGFP) or shRNA targeting 
human MED23 (sh23-9), were either mock transfected, or transfected with 1 µg/ml of 
poly (I:C) and harvested 2 hrs later. Chromatin immunoprecipitation was carried out 
using anti-RNA Pol II and isotype control antibodies, immunoprecipitated DNA was 
assessed by RT-qPCR. Data represent three technical replicates, and is presented 





A previous paper has shown that MED23 is required for induction of type III IFNs, 
likely through an interaction with IRF7
78
. Our data indicate that MED23 is required 
for induction of both type I and type III IFNs. While we did not observe IFN induction 
with overexpression of MED23 alone, MED23 appeared to increase IFN induction 
when co-expressed with either IRF7 or MAVS. Cells depleted of MED23 also showed 
reduced ability to express both type I and type III IFNs in response to cytoplasmic 
synthetic dsRNA and dsDNA analogues, as well as infection with an RNA virus. This 
critical role in innate immune responses is consistent with previous findings in 
Drosophila, where MED23 was shown to be required for heat-shock-specific gene 
expression via an interaction with Dif – a functional homologue of mammalian NF-
kB – and the Heat shock transcription factor (Hsf)217. The heat shock response was 
recently shown to be vital in controlling infection by RNA viruses in Drosophila218. 
 
The observation that Med23-/- cells undergo genetic compensation is interesting, albeit 
a rather surprising one. MED23 has been shown to be required for induction of the 
Egfr1 gene in embryonic stem cells downstream of phosphorylated ternary complex 
factor ELK1
160
. Using the same Med23-/- murine embryonic fibroblasts used in our 
experiments, Balamotis et. al. showed that Egfr1 transcription still occurred in these 
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cells despite the lack of MED23
161
. While the authors, using transcriptome analyses 
and chromatin immunoprecipitation assays, showed that different ternary complex 
factors bound to the same regions as ELK1 to induce transcription of Egfr1 in the 
fibroblasts, it will be interesting to see if transcriptional adaptation played a role there 
as well.  
 
Our data indicate that MED23 is required for Mediator recruitment and induction of 
genes downstream of activated IRF3, but not those dependent on NF-kB activation. 
This is consistent with published data that shows MED17 as the critical Mediator 
subunit required for recruitment of Mediator to transcription sites of NF-kB-
dependent genes
168
. Although both IRF3 and NF-kB extensively cooperate following 
activation to promote transcription of the same genes, IRF3 was shown to be partial 
towards de novo recruitment of RNA Pol II while NF-kB showed a greater tendency 
to mediate release of RNA Pol II paused at target sites
169
. As the Mediator is critical 
for both RNA Pol II recruitment and commencement of transcription elongation
79
, it 
will be interesting to see if, and how, this is affected by the difference in the 
mechanism of Mediator recruitment.  
 
MED23 depletion did not affect signalling downstream of IFNAR receptors, 
indicating that it is not required for Mediator recruitment by IRF9. This is 
understandable, considering that STAT2 – a component of ISGF-3 together with 
STAT1 and IRF9 – is likely able to recruit the Mediator via an interaction with 
MED14
210
. Given that IRF7 and IRF3 require MED23 for transcriptional activation, 
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it is possible that other positive regulatory IRFs such as IRF1 and IRF5 will also share 
this property. 
 
The events taking place in the nucleus during type I IFN induction have been studied 
extensively. However, much of these studies precede the discovery of the Mediator 
complex, and therefore do not take it into account
71
. To the best of our knowledge, 
this is the first description of the mechanism of Mediator recruitment downstream of 
activated IRF3. Further work is required to gain more insight into this process, 
including the nature of the interaction between IRF3 and MED23, as well as the role 
of post-translational modifications, especially considering the recent resolution of the 
structure of MED23
219
. Additionally, further work is still required to determine the 

























Conclusion and future work 
 
The first two aims of this thesis were to define additional innate immune mechanisms 
employed in the detection of MNV1 and clarify the mechanism of VF1 antagonism of 
host IFN responses. We described the presence of a RIG-I/STING-dependent innate 
response pathway that restricts the replication of noroviruses, and demonstrated an 
attempt by the murine norovirus to subvert it through expression of VF1. Our data 
largely agree with, and contribute to the current body of work on IFN responses to 
noroviruses, while also exposing the need for future work to understand the interplay 
between MDA5 and RIG-I in norovirus-infected hosts, as well as the cognate PAMPs 
recognised during infection with noroviruses. Future studies are also needed to further 
understand the function(s) of VF1 (including its ability to inhibit apoptosis), and other 
potential strategies used by noroviruses to evade host innate immune responses. 
 
The last aim of this thesis was to explore other innate immune mechanisms at play in 
the restriction of RNA viruses. While we were unable to show peroxisomal 
localisation of MED23, we observed that it promotes the induction of both types I and 
III IFNs. We showed that depletion of MED23 leads to a reduction in expression of 
both type I and type III IFNs in human and mouse cell lines transfected with synthetic 
dsRNA. We also showed that Med23-/- cells undergo genetic compensation, 
suggesting a critical role for MED23 in this pathway. Mechanistically, we showed that 
MED23 interacts with IRF3, and is required for recruitment of RNA Pol II to 
promoters of IRF3-dependent genes. Altogether, our data indicate that MED23 plays 
an important role in antiviral responses by coupling IRF3 activation and RNA Pol II 
recruitment. Further work is required to gain more insight into this process, including 
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the nature of the interaction between IRF3 and MED23, as well as the role of post-
translational modifications. Additionally, further work is still required to determine 
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